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Abstract
Cancer has become one of the dominant diseases worldwide, especially in western
countries, and radiation therapy is one of the primary treatment options for 50% of all
patients diagnosed. Radiation therapy involves the radiation delivery and planning based
on radiobiological models derived primarily from clinical trials. Since 2015
improvements in information technologies and data storage allowed new models to be
created using the large volumes of treatment data already available and correlate the
actually delivered treatment with outcomes. The goals of this thesis are to 1) construct
models of patient outcomes after receiving radiation therapy using available treatment
and patient parameters and 2) provide a method to determine real accumulated radiation
dose including the impact of registration uncertainties.
In Chapter 2, a model was developed predicting overall survival for patients with
hepatocellular carcinoma or liver metastasis receiving radiation therapy. These models
show which patients benefit from curative radiation therapy based on liver function, and
the survival benefit of increased radiation dose on survival.
In Chapter 3, a method was developed to routinely evaluate deformable image
registration (DIR) with computer-generated landmark pairs using the scale-invariant
feature transform. The method presented in this chapter created landmark sets for
comparing lung 4DCT images and provided the same evaluation of DIR as manual
landmark sets.
In Chapter 4, an investigation was performed on the impact of DIR error on dose
accumulation using landmarked 4DCT images as the ground truth. The study
demonstrated the relationship between dose gradient, DIR error and dose accumulation
error, and presented a method to determine error bars on the dose accumulation process.
In Chapter 5, a method was presented to determine quantitatively when to update a
treatment plan during the course of a multi-fraction radiation treatment of head and neck
cancer. This method investigated the ability to use only the planned dose with deformable
image registration to predict dose changes caused by anatomical deformations.
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This thesis presents the fundamental elements of a decision support system including
patient pre-treatment parameters and the actual delivered dose using DIR while
considering registration uncertainties.

Keywords
Radiation therapy, image-guided radiation therapy, adaptive radiation therapy, decision
support, deformable image registration, registration error
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Chapter 1

1

Introduction

1.1

Overview

Compared to most other diseases cancer presents a unique problem of unregulated cell
growth, resulting from a wide range of cell mutations. These mutations create many
different cancer types and pathologies each responding differently to treatment. Radiation
therapy has been used since the early 1940s to provide effective treatment for many
cancers and is currently one of the primary treatment options for cancer. Through
different delivery methods and geometric targeting high levels of radiation can be
delivered to cancer cells, while trying to spare surrounding healthy tissue. The challenge
is to ensure that the necessary amount of radiation is delivered to a cancerous tumour to
treat a patient’s disease.
Unlike other treatment modalities, the intended amount of radiation to specific organs or
regions can be visualized from a 3D computerized calculation (treatment plan) and be
used to optimize disease control and limit toxicity. Radiation therapy has progressed over
the last two decades from basic target coverage to “precision” coverage for the benefit of
improved tumour control and reduced normal tissue damage. Unfortunately with
precision coverage the static treatment plan (created on the patient’s pre-treatment
anatomy) becomes less accurate as treatment progresses and the patient’s anatomy
changes requiring new tools to characterize changes in accumulated dose during
fractionated treatment. Image guidance was introduced to limit positioning errors and
monitor for anatomy changes but it could not effectively compensate for anatomical
deformations because reducing position errors is insufficient for optimized dose
distributions. Even if the plan can be adapted when significant anatomical changes are
noticed, it is currently difficult to determine the accumulated dose on a per voxel basis
and the correlation with outcomes.
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Deformable image registration (DIR) is a graphics tool that maps every point in a
reference volume to the corresponding point in another image volume. With DIR and
image guidance the dose received in every fraction can be mapped back to the original
planning volume determining the cumulative delivered dose. However, DIR currently
contains inherent uncertainty introducing quandary to the record of delivered dose.
Currently, in radiation therapy, there is lack of information on the actual delivered dose
due to limitations in image registration accuracy preventing effective correlation with
patient outcomes. Historically, treatment outcomes were correlated only with patient’s
planned dose distribution calculated prior to the start of treatment. The inclusion of
detailed information about planned and actually delivered dose would improve the
predictive power of treatment outcomes and optimize/personalize the treatment process.
Ideally with an accurate record of the distribution of the received dose paired with
outcomes and pre-treatment parameters improved personalized medicine can be realized.
The following sections will introduce cancer, adaptive radiation therapy and deformable
image registration to provide context for later chapters.

1.2

Cancer

Since the beginning of human history, our mortality has been tested from predators,
environmental disasters, war and disease. Through cooperation and innovation, we have
thrived in our environment and extended the average human lifespan from 30 years in the
1800s to 67 years in the year 2000 [1]. This modern longevity can be attributed to better
nutrition and modern medicine. Traditionally medicine sought to cure diseases from
foreign sources including bacterial infections and viruses or to repair physical damage or
birth defects. As many life-threatening diseases and conditions were eradicated and with
increased life expectancy, cancer became much more prevalent especially in developed
nations. As a fundamentally different type of disease, cancer required an entirely different
approach.
Cancer is not directly caused by any foreign organism or event but occurs when there is a
significant mutation in a cell’s DNA, making cancer cells grow uncontrollably without
normal growth regulation. The primary symptoms of a cancer cell are rapid and
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uncontrolled growth and loss of the cell’s original function. The lethality of cancer is
caused by the tumour’s necessity for oxygen, nutrients and space, ultimately starving
surrounding healthy tissue as it spreads and grows. Treatment of cancer is difficult since
it has few differences from healthy cells, unlike bacteria, and the immune system can no
longer effectively combat it. Unlike other diseases the mutations at the root of cancer are
a fundamental part of cellular evolution, making cancer inescapable.
Throughout the developed world cancer is the leading cause of death, making its
treatment and management paramount. Studies have shown specifically in Canada 1 in 2
people will get cancer in their lifetime [2]. With such a large burden, the management of
cancer has become a major component of healthcare costing 4.4 billion dollars in 2008 in
both direct health care costs and lost productivity [2]. There are currently three main
treatment modalities for cancer management; i) surgery, ii) systemic therapy and iii)
radiation therapy. Surgery is the desired option, physically removing the malignancy but
only applies to removable tumours and patients healthy enough to endure the procedure
and recovery. Systemic therapies use drugs to treat cancer systemically but can create
significant toxicities since the effects are typically poorly targeted. Radiation therapy is a
non-surgically invasive targeted therapy, capable of treating a majority of patients,
producing limited toxicity and easily combined with other therapies. The complexity of
cancer diagnosis and treatment (with multiple modalities) requires accurate modelling to
determine the optimal treatment technique. Currently, making a decision for treatment is
challenging, because outcome prediction is made based on averaged data, while patient’s
anatomy or disease may vary significantly. For modelling to be effective, a complete
account of all treatment parameters is required.

1.3

Radiation therapy

Radiation therapy employs ionizing radiation to treat cancer, with the goal to deliver
sufficient levels of radiation dose to a tumour while sparing surrounding healthy tissue.
Quantitatively, the required dose to kill cancerous cells is given by tumour control
probability (TCP) models [3-5]. Tolerance doses for organs at risk (OAR) are obtained
from normal tissue complication probability (NTCP) models [6-7]. Recently the
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QUANTEC publications [8] provided updated recommendations for limiting dose/volume
parameters for OARs.
Radiation can be delivered externally (external beam radiation therapy) or from implanted
radiation sources (brachytherapy). The primary mechanism of radiation therapy is to
fatally damage cancer cells by breaking their DNA leading to cell death. Every radiation
therapy treatment plan begins with a CT simulation representing the patient’s anatomy in
three dimensions and depicting (and contrasting) the electron density of different tissues
required for dose calculation. An example of a CT simulation is presented in Figure 1-1
with the axial, sagittal and coronal cross-sections of a CT volume with the gray scaling
illustrating the different electron densities. Contours are produced to identify individual
tissue types, OAR and target the tumour.

Figure 1-1: CT image study of head and neck region a) axial b) sagittal c) coronal.

The radiation treatment plan is optimized for the patient’s contoured CT simulation to
select the best combination of radiation beams produced at different angles overlapping
on the target region demonstrated in Figure 1-2.
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Figure 1-2: Image of overlapping intensity modulated radiation therapy (IMRT) fields generated by
specific multi-leaf collimator (MLC) configurations. Colour map represents the dose distribution.
Image from http://www.ofunachuohp.net/rt/technique.html.

A radiation treatment plan is generated as the result of applying targeted beams to a
tumour while limiting the dose to organs at risk. Historically treatments were delivered
using large rectangular fields with wedged beams or lead blocks which could cause
significant toxicities from less conformal dose distributions. With higher precision
delivery tools developed in the mid-nineties such as multi-leaf collimators (MLC) and
Intensity-modulated radiation therapy (IMRT) toxicity was reduced compared to earlier
treatment techniques [9]. In modern radiotherapy practice, there are many degrees of
freedom, including beam angles, energy and modulation utilizing an MLC that defines the
treatment plan. An MLC is a series of tungsten segments that shape the radiation field
during treatment shown for each beam in Figure 1-2. Optimization of these parameters to
satisfy the prescribed dose constraints creates highly conformal dose distributions,
displayed in the centre of Figure 1-2. With further improvements and the combination of
arcing, varied dose rate and beam modulation, volumetric arc therapy (VMAT) was
developed in 2010 improving plan quality further [10-13] with reduced treatment times.
As technology developed, the ability to deliver radiation with pinpoint accuracy has
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become possible, but the difficulty lies with adapting to anatomical changes during
treatment while maintaining the same precision and accuracy.

1.4

Patient outcomes

Radiation delivery has improved significantly with the introduction of new techniques
including IMRT, VMAT, and proton therapy, but though technically superior they have
shown limited improvements in patient outcomes especially when related to their cost.
Health care costs are increasing unsustainably in the developed world with the USA
spending 17.2% of their GDP on healthcare in 2017 as shown from the OECA health
statistics [14]. Much of the increase in spending will come from private insurers
increasing premiums, funding cuts to other programs and increased taxation. The concept
of value in healthcare has been largely avoided, especially within a private health care
system like in the US. The value approach has attracted considerable attention in many
countries employing a single payer system (i.e. Canada) leading to a near 50% reduction
in health care spending per capita compared to the US [14] without compromising health
care. The concept of value is simple, benefit (i.e. patient survival or quality of life)
divided by cost but in practice, it is more difficult to define. As costs continue to soar
with the development of new drugs, imaging and technology the value we are receiving is
decreasing and this rate of development may challenge the benefits of randomized clinical
trials. To justify higher cost options healthcare service providers must provide evidence
of extended quantity and quality of life obtained through impactful outcome research.
Outcome research is an integral part of the value discussion helping to define the realworld benefit from new treatments and technologies. Only with a clear definition of both
the benefits and the opportunity costs of medical treatments can healthcare become
sustainable. This issue of value-centred care has been discussed in radiation oncology
[15-17] where patient outcomes and cost can vary greatly.
The difficulty for radiation oncology is how to effectively measure benefits and cost
while accounting for both patient-specific parameters and radiation delivery options. As
radiation treatments progress there are biological and anatomical changes that impact how
the radiation is received making it difficult to compare treatments based only on their
initial plans. For example, recent studies predicting patient outcomes avoid including
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specifics on how the treatment was delivered [18, 19] and consider using more advanced
imaging parameters like Radiomics [20]. Even in studies trying to model radiation effects
on TCP and NTCP only the prescribed dose is considered [21, 22]. For a true assessment
of value, a better understanding of what treatment was delivered is necessary otherwise
any real effect could be misinterpreted.
In chapter 2 we have presented a determination of overall survival for liver cancer
patients and include treatment parameters, and demonstrate the poor prognostic value of
using only the prescribed dose. A multivariable analysis presented the possibility of the
advantage of including additional parameters namely a uniform low dose to surrounding
tissue [23]. Previous predictive liver cancer models had not included the effect of
radiation dose [24, 25] or did not include all other pertinent liver function and disease
parameters [26].
The inclusion of the actual delivered dose that accounts for daily anatomy changes
enhances the predictive power. Decision making based on complex data including pretreatment patient characteristics, planning parameters, delivered dose is technically
feasible in the era of integrated electronic records and treatment planning systems as
demonstrated in our previous work on the design of a clinical database system [27]. With
the complete picture of treatment delivery more clinical trials and machine learning can
be performed to obtain a better understanding of the value added by new treatment
techniques.

1.5

Image guided radiation therapy

Typical radiation therapy treatments are delivered over multiple fractions ranging from
three fractions delivered over the course of a week, to 30 or more. As treatment
progresses it is difficult to determine how well the delivered dose matches the prescribed
dose without additional imaging and tracking data. Historically as radiation treatment
plans became more advanced daily imaging was introduced to ensure patient alignment to
the planning position before each treatment and check for significant anatomical changes.
This process is called Image-guided radiation therapy (IGRT) and involves patient setup
using external markers (tattoos and immobilization devices) followed by imaging
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performed with onboard megavoltage (MV) or kilovoltage (kV) imaging systems. Once
images have been obtained couch shifts are applied to ensure the patient is in the correct
(planned) position relative to the treatment field. Current forms of image guidance
include 2D kV, MV CT (used on Tomotherapy), CT on rails and cone beam CT (CBCT).
A radiation therapy treatment plan is optimized to deliver a radiation dose to the gross
tumour volume (GTV) with margins added to incorporate potential microscopic disease
spread creating a clinical target volume (CTV). Furthermore, to account for set up and
radiation delivery errors an additional margin is introduced creating the planning target
volume (PTV). These margins were defined by the international commission on radiation
units and measurements (ICRU) reports 50 [28], 62 [29] and 83 [30]. With increased
margins delivering higher levels of radiation to the PTV became challenging because the
PTV can overlap or be in close proximity to sensitive organs. Image-guided radiation
therapy improves the accuracy of treatment delivery with smaller PTV margins and
allows for target conformal treatments with higher doses.
Clinically IGRT has paved the way for more aggressive treatment options providing
better outcomes for patients without the risk of toxicities. A study by Zelefsky et al.
demonstrated reduced urinary toxicity, and improved survival for high-risk prostate
cancer patients using IGRT, compared to standard IMRT [31]. There have been recent
studies describing the improvements brought by IGRT for prostate [32-34], lung [35],
brain [36] and head and neck [37]. As the cost of implementing IGRT is large it is
important to optimize the IGRT process by making it patient specific and determine the
sub-group of patients and disease sites where IGRT has a significant impact on clinical
outcomes. IGRT also provides accurate records of the patient’s anatomy throughout
treatment.

1.6

Adaptive radiation therapy

Radiotherapy is planned on a patient’s static anatomy provided by CT simulation before
the start of treatment. As the treatment fractions are delivered the patient’s anatomy often
changes and affects how the dose is deposited. These dose changes to the target and
surrounding healthy tissue influence disease control and/or increase the risk of
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complications. To counteract anatomical changes the treatment plan can be modified via
adaptive radiation therapy to minimize deviation from the original plan. Such
modification is only needed for sites where anatomical changes are important based on
the impact on the cumulative dose distribution.
Adaptive radiation therapy is the modification of a plan during a multi-fraction radiation
treatment in response to changes in the patient’s anatomy and disease. These changes can
include weight loss, body functions (bladder/rectum filling/emptying), breathing, setup
errors and tumour progression or shrinkage. Multiple studies have shown significant
benefits in survival and reduced toxicity by adapting treatments [38, 39]. Unfortunately,
there is currently no standard adaptation strategy with different centres and studies having
different approaches. Nijkamp et al. adapted treatment after fraction 6 out of 39, using the
average PTV measured from the previous 6 treatments [40]. Whereas earlier studies
would perform a new CT simulation after a specific amount of dose has been delivered to
a tumour [41, 42]. Most institutions use image guidance to monitor the patient’s anatomy,
using different image matching techniques and action levels. When large changes are
observed the treating physician can require an adaptation to their treatment and he/she is
responsible for the final decision. Such a decision is typically based on observations of
anatomy changes only, while the clinical assessment should include changes in the dose
distribution. Currently, this dose-effect evaluation is achieved only by repeated full CTsimulation with contouring and dose calculation. In chapter 5 a method is presented to
provide an automatic daily evaluation of the necessity of plan adaptation for head and
neck cancer without additional imaging and dose calculations. Without a standard
approach, comparison of treatment outcomes with respect to radiation treatment is
difficult since they will be adapted at different points.
Any radiation treatment plan is dependent on the imaging acquired for diagnostic or
planning to provide a complete picture of a patient’s anatomy and disease. All modern
imaging modalities produce a 3D volume with voxel values representing electron density,
cellular structure or cellular processes. Radiation therapy is targeted to voxels suspected
of cancer and avoids voxels of sensitive structures typically highlighted by contours.
Unfortunately, contoured regions are only present on the planning CT simulation and can
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change significantly throughout treatment. No longer can the planned dose to individual
voxels or structures be used to correlate with outcomes without accounting for anatomy
change and plan adaptation. Currently, the only effective method to track dose changes
from anatomy change and to perform plan adaptation is with deformable image
registration.

1.7

Deformable image registration

1.7.1

Background

Image registration is the process of pairing two image volumes together that are both
derived from the same object. There are multiple objectives for employing image
registration, for example, registering images of an object viewed from different points,
different image modalities or after experiencing deformation. Each of these scenarios
occurs frequently for medical imaging using CT, magnetic resonance imaging (MRI) and
positron emission tomography (PET). Independent of the application, the goal of image
registration is to map every pixel on every slice (or voxel in 3D) from one image space to
another.
In radiotherapy, image registration is primarily used to delineate cancerous regions
(GTV) and sensitive structures from diagnostic images (MRI or PET) and propagate the
contours to the planning CT study. MRI is commonly used for superior soft tissue
contrast compared to CT for target delineation for many treatment sites including prostate
[43], cervical [44], brain [45], and head and neck [46]. But MRI does not contain the
electron density values required for radiotherapy planning. Image registration can
facilitate the transfer of diagnostic information from MRI to CT to facilitate dose
calculation and treatment planning. An example of improved target delineation is
presented in Figure 1-3a for the bladder, tumour and rectum in the female pelvis [44].
Another important accompanying imaging modality is PET, which can locate and stage
disease using its metabolic activity detected by specifically labelled radioisotopes,
primarily fluoride 18. PET imaging has greatly improved target delineations [47]
especially for thoracic cancers [48, 49]. When a PET image is registered to a planning
CT, a “fused” image is generated indicating areas of glucose uptake or cancer
aggressiveness as a colour map shown in Figure 1-3b.
10

Figure 1-3: a) checkerboard overlap of MRI and CT of female Pelvis [44] B) CT image and CT image
with PET colour map showing metabolic activity and highlighting lesion [50]. Permission for both
figures is presented in Appendix A.1 & A.2.

As treatment methods improved, IGRT and adaptive radiation therapy became common,
traditional rigid registration was no longer always suitable because patient’s anatomy
would deform non-linearly throughout treatment. Now multiple image studies are
collected at different time points which are anatomically different. To solve this problem
deformable image registration (DIR) was introduced [51] to map every point between
image spaces non-linearly, producing a deformation vector field (DVF), an example
illustrated in Figure 1-4. A DVF can deform contours from the planning image to daily
images and after calculating the dose distribution compare and accumulate the dose from
each fraction. The final goal is to effectively track and accumulate the radiation dose
being delivered from each fraction to correlate real delivered dose with patient outcomes.
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Figure 1-4: Example of a deformation vector field, shown in the interface from the Varian Velocity
software suite.

1.7.2

DIR fundamentals

The results of a DIR for an individual point can be interpreted as the vector between the
point from the original image space (x,y,z) to the new image space (x’,y’,z’). When used
for 3D medical image volumes the problem becomes complex by assigning deformation
vectors to millions of voxels with different physical properties. DIR has been a longstanding tool in computer vision with its recent surge in popularly due to improvements in
data storage and computation [52]. Registration algorithms can be defined by four main
characteristics: i) transformation type ii) image similarity metric iii) regularization, and
iv) optimization. Many fundamentals of image registration have been explored in the
textbooks Medical Image Registration by J Hajnal [53] and Numerical Methods for Image
Registration by J Modersitzki [54]. Other informative journal articles describing the
fundamentals behind DIR are by Glocker et al. [55] and Oh et al. [56].

1.7.3

Transformation

When two image volumes (referred to as the moving and final image volumes) are
presented the first question is how to match them together or deform the moving image to
match the final. The simplest option is to use a combination of affine transformations
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including translation, rotation and scaling producing a “rigid registration” with the shape
of objects conserved. As the complexity of the transformation increases more parameters
are added to explain the local deformation at different points throughout the image. The
deformation of these points can be driven by different methods and linear combinations
of spline functions (e.g. B-spline) are commonly used. B-spline methods linearly combine
different B-spline functions to deform all points from the moving image to the final
image. Interpolation between control points can also be performed following the
combined B-spline functions, an example of a B-spline interpolation is shown in Figure
1-5a. Spline-based transformations are used in multiple studies [57, 58] and within the
open source Insight segmentation and registration toolkit (ITK) registration software [59].
Splines are a parametric model and can be solved rapidly since each point is not solved
individually with a resulting DVF looking similar to Figure 1-4.
Different from spline methods the popular ‘Demons’ method is able to represent the DVF
at each voxel of the volume by calculating a demons force at each voxel based on the
local intensity gradients. The demons method has been adapted in many commercial
systems [60-61] because of high-resolution DVFs but has difficulties driving
deformations in regions of low-intensity gradients. A demons transformation can produce
fine local deformations as shown in Figure 1-5b for an example of the shrinking of a
small structure.

Figure 1-5: a) Example of a 1D spline interpolation b) example of demons DVF vector for a small
object shrinking from the bottom. Produced in MATLAB.
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To better model physical systems improved algorithms were developed using finite
element modelling [62] and Hooke’s law to govern the resistance to deformation and
elasticity of biological tissue. Most medical CT and MRI image studies have important
organs contoured and can also highlight regions of bones, air and soft tissue all with
different intrinsic mechanical properties. Applying the different mechanical properties
from contoured images with finite element methods allowed for a biomechanical model
for image transformation producing highly accurate results, implemented in the Ray
station treatment planning systems developed from RaySearch Laboratories [63]. Though
its results have been promising it currently requires contoured images for the best results,
which are difficult and time-consuming to produce with daily image guidance. Contoured
images are used to assign mechanical properties to specific voxels, and to model the
surface deformations of structures.

1.7.4

Image similarity

With a transform applied to the moving image, a measure of image similarity is required
to evaluate how accurately the deformed volume matches the final volume. There are two
main categories of image similarity metrics based on landmarks and image intensity
values. Landmark or feature methods locate important unique regions including corners,
edges or object centres and try to match their position between the transformed moving
and final image volume. Though simple to understand, landmark methods are rarely used
for driving a DIR because of large calculation times and the requirement of the objects to
be imaged clearly. Methods based on image intensity are more general and have been the
standard for all DIR algorithms requiring only the intensity values at each voxel.
Image similarity metrics based solely on image intensity values are the mathematical
relationships between two data sets, arranged in a 2D or 3D matrix. One of the simplest
metrics is the sum of squared difference (SSD).
= ∑ (

−

)

(1)

Where N is the total number of voxels i, XM and XF are the voxel intensity values for the
deformed moving (subscript M) and final (subscript F) image, respectively. SSD is very
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easy to calculate only requiring N operations for any image, but it is limited and has
difficulties with noisy images and any differences in imaging protocol or modality. To
improve upon the SSD other metrics are used including normalized cross correlation
(NCC), equation (2), with standard deviation σ and
=∑

(

−

)(

−

)

being the mean value per image.
(2)

For cross modality DIR (for example CT to MRI, or CT to CBCT) both SSD and NCC
metrics can suffer due to non-linear differences in image intensity values in the same
material (i.e. bone or soft tissue).
A different approach is the concept of mutual information (MI), evaluating not the image
intensities but analyzing the “information” present in both images. MI is calculated by
looking at the probability that intensity values from the moving image match with values
from the final images. For example, if the probability of value X from the moving image
matching value Y from the final image is very high, the agreement is consistent. If the
probability of other value pairs is high, you can assume that the registration is accurate. A
more in-depth explanation of MI can be found in Hill et al [64]. Any DIR with multimodal imaging (e.g.CT-MRI) exclusively uses MI to overcome the conceptually different
voxels values [65].

1.7.5

Regularization

Applying different image transformations to maximize image similarity can produce
various solutions that “best” match two images together. Unfortunately, image similarity
metrics fail to consider the physical limitations of the objects, producing solutions that
deform across large distances or collapse many voxels down to a single point. To
constrain the registration process, an additional regularization term is used in conjunction
with the image similarity. As the image similarity drives the registration towards
matching both images, the regularization term will penalize certain transformations based
on the application. For example, registrations of the brain and skull will impose strict
volume conservation, unlike registrations of the abdomen or thorax which would apply
regularization to ensure smoothness.

An example of a regularization term
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( )=

∫‖∇ ( )‖

(3)

promotes smoothness by penalizing first order derivatives, where T is the transform (or
DVF) and α is a weighting parameter.

1.7.6

Different algorithms

Through various combinations of transformations, image similarity metrics and
regularization different DVFs will yield significantly different results. Depending on the
final application or software environment, different commercial vendors have
implemented their own unique algorithms. Popular commercial products for radiation
therapy include RayStation (RaySearch laboratories, Stockholm, Sweden), MIM Software
(Cleveland, OH, USA), Velocity (Varian Medical Systems, Palo Alto, CA). For the
treatment planning system Raystation the DIR algorithm named ANACONDA (explained
in more detail by O. Weistrand et al [63]) is incorporated, using a correlation coefficient
similarity metric and two forms of regularization ensuring smoothness and shape based
regularization. Shape-based regularization assumes that anatomical regions are defined by
3D meshes and the DIR must deform the mesh in a consistent and physical manner. Also,
the ANACONDA algorithm can include contour information both as a penalty term in the
regularization, or simply to focus the registration to important regions.
Unlike Raystation, the algorithm from MIM software is less documented but is an
intensity-based free-form algorithm, using the sum of the squared difference as the
similarity metric [66]. Velocity uses an intensity based b-spline algorithm, with mutual
information as a similarity metric [67]. Currently, commercial vendors of DIR do not
report the specifics of their propriety algorithms, resulting in most DIR products being
implemented as “black box” systems. Even with the most advanced DIR algorithm
inaccuracies will be present when attempting to match millions of voxels between image
studies and the problem gets worse when algorithm specifics are locked within black box
systems. These inaccuracies can be harmless or lead to miss-registering a tumour to a
sensitive structure.
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1.8

Registration error

Deformable image registration has a vast scope working with deformed image sets,
comparing time points, or different imaging modalities. Because DIR at first glance can
appear to accurately register two images, registration errors can be very difficult to spot
making additional evaluation necessary. For this reason, many studies have been
published producing different methods or metrics to evaluate the “quality” or accuracy of
the DIR. The goal of these studies is to provide the user with a means to compare and
evaluate different registrations and provide information where a particular registration
algorithm is most accurate.
The two most common methods for evaluating DIR are comparing contours or
segmentation and propagated manual landmarks. Contour propagation has always been an
attractive feature of DIR and comparing the generated contours to expert manual contours
has been the standard for registration benchmarking. The common metric for contour
comparison is the DICE coefficient measuring the overlap of two contours and it has been
used in the majority of studies [68-71]. Unfortunately, contour methods fail to evaluate
registration performance within structure boundaries which is essential for accurately
determining accumulated radiation dose. Another common method is comparing the
propagation of landmark sets produced by experts [72]. This method uses landmarks
located in two image sets and finds the distances between actual landmarks and DIR
predicted landmarks in the final image. Landmarks provide discrete measurements of DIR
accuracy but they need to be located manually. In order to overcome this problem in
Chapter 3, an automatic method using the scale-invariant feature transform is presented
and tested against manual and expert landmarks.
Some early examples of DIR accuracy measures were the inverse consistency or
transverse consistency errors describing how a DVF mapped the moving image to the
final image and vice versa [73]. In principle consistency measures are good “warning”
signs of unrealistic registrations, but can’t adequately predict the magnitude of error as
shown by Bender et al. with poor correlation to registration errors [73]. Methods looking
at mechanics-based metrics such as unstable energy by Li et al. [74] yielded improved
correlation with registration error. Building on the idea of consistency metrics, Saleh et al.
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developed the distance discordance metric (DDM) [75] that uses registrations between
images within the same longitudinal study to measure consistency and demonstrated
higher correlation than the original consistency metrics alone. Other studies attempted to
use different statistical measures to determine registration uncertainty using bootstrapping
[76] and the Cramer-Rao bound method [77]. More advanced methods were developed to
specifically evaluate a DIR with respect to the physical deformation of tissue. For
example, Zong et al [78] used finite element analysis to simulate the elastic properties of
soft tissue to measure the internal forces.
Predominantly DIR evaluation methods are derived to compare and contrast different
algorithms to best determine the most accurate and efficient algorithm for specific
applications. This approach has been followed in multiple studies comparing different
algorithms by comparing their DICE scores, or landmark registration errors for given test
sets [79, 80]. Work by Kirby et al. constructed realistic 3D phantoms for the head and
neck and male pelvis to evaluate several DIR algorithms [81, 82]. What needs to be
determined is how this error affects the final results for a dose accumulation and if
uncertainty bounds can be added to any final result. Figure 1-6, an example of using DIR
to match a single point on the boundary of the rectum from two CT studies shows how
the dose results can vary significantly depending on the registration error.

Figure 1-6: Example of the effect of registration error. Colour map is the radiation dose. Point A)
miss-registration but still on the boundary, B) miss-registration still within boundary and C) missregistration with same dose level.

These errors may not be significant for a single registration, but the errors can cumulate
as the radiation dose is accumulated from multiple studies. A study by Risholm et al.
demonstrated a DIR algorithm that inherently produced the uncertainty of every vector
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within the DVF [83]. Using this algorithm, uncertainty bounds could be added to any
final results. For example, in a later study, they added uncertainty bounds to a dose
accumulation showing their impact on the final accumulated dose distribution [84].
Though the work by Risholm et al. demonstrated the possibility of applying uncertainty
information, it was only possible with their custom DIR algorithm that was not designed
for clinical practice. What is required for clinical practice is for commercial DIR
algorithms to provide DIR uncertainty and accuracy information for each DVF to provide
realistic results? In chapter 4 a method of incorporating predicted DIR uncertainty into a
commercial DIR algorithm is demonstrated. Having a characterization of the uncertainty
of DIR with deformable dose accumulation can provide physicians with useful
information for making a decision on plan adaptation and dose prescriptions. Therefore,
including registration uncertainty in the dose accumulation process can provide a more
accurate account of radiation delivery throughout a multi-fraction treatment, producing
more powerful predictive models of disease control and normal tissue complications.
With more powerful predictive models treatment options can be determined uniquely for
each patient and their desired outcome creating personalized medicine in radiotherapy.

1.9

Decision making in radiation therapy

Since 1951, when the first Co-60 radiation treatment unit was used in London, Ontario for
cancer care, tremendous progress in technology has occurred. The huge amount of
clinical evidence has been obtained through clinical trials with patient participation,
laboratory experiments and various comparative studies of treatment outcomes reported
in scientific journals. In practice, treating physicians are often deciding on the best
possible treatment of patients quickly based primarily on the physician’s education and
personal experience. Yartsev and Mackie [85] proposed a scheme for decision making
that involves creating a model for radiation therapy based on a large and constantly
growing database of patient’s personal features, parameters of treatment, clinical
outcomes and patient’s preferences. An important aspect of such a model is quality data
accounting for all elements of treatment to facilitate machine learning methods and allow
the models to incorporate incoming patient data. In this thesis, we consider several key
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components of the decision-making process, schematically presented in Figure 1-7
highlighting the contributions from each chapter of the thesis.
This schematic describes the connection of the planning data (left side) and the patient
data (right side) and the different processes required to link them together described
through specific chapters. The first link is the modelling of patient data to determine
optimal treatment plans for the desired patient outcomes. In Chapter 2 a multivariable
model is produced linking patient, treatment and outcomes data producing two clinical
nomograms to help guide physicians with treatment decisions. The second link is between
the planning image and treatment images provided through deformable image registration
and image guidance (IGRT). DIR is a key element of this link since all daily changes are
deformable. Though DIR is an excellent and necessary tool, it has unknown inaccuracies
that need to be considered when used clinically. In Chapter 3 an automatic DIR
evaluation method was presented allowing DIR to be evaluated routinely whenever it is
applied.
The third link is determining the real delivered dose from the planned dose using daily
images and deformable image registration for dose accumulation. Similar to the second
link deformable image registration is required and its accuracy needs to be considered in
the final dose accumulation. Chapter 4 created a method to incorporate DIR uncertainty
into the dose accumulation process, to determine what dose was actually delivered. The
final link is between the original treatment plan and the adapted treatment plan initiated
after significant anatomy change was observed. In Chapter 5 a method for quantitatively
evaluating the necessity of plan adaption is presented in order to provide more accurate
and consistent plan adaptation strategies. The thesis chapters each provide different
necessary elements required to incorporate patient data to determine patient outcomes
from their cancer treatment.
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Figure 1-7: Schematic for outcome-driven decision making in personalized radiotherapy.
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1.10 Research goals and objectives
The research outlined in this thesis focuses on two main goals i) to construct a method of
including radiation treatment parameters for prediction of clinical outcomes ii) to provide
the methods of tracking accumulated dose in multi-fraction treatment with known
registration uncertainty. These goals were achieved through the following objectives
including the modelling of patient survival in radiation therapy and the practical
applications of DIR:
1. Find the significance of treatment and pre-treatment parameters in modelling patient’s
overall survival and construct nomograms.
2. Produce and evaluate an automatic landmark generation method and test against both
amateur and expert manual landmarks.
3. Determine the effect of registration error on measuring the daily dose using DIR.
4. Evaluate the ability to decide when to adapt a treatment plan for head and neck cancer
patients using DIR without a dose recalculation.

1.11 Thesis outline
1.11.1 Modelling of overall survival for hepatic carcinoma or liver
metastasis receiving radiotherapy (Chapter 2)
There are many parameters influencing treatment success in liver cancer including patient
and treatment parameters. In this study, patients diagnosed with hepatic carcinoma and
liver metastasis were analyzed with multivariable Cox regression of overall survival. The
results were two nomograms for primary hepatic and metastatic patients demonstrating
the impact of radiation prescription and other patient parameters on overall survival. This
chapter is based on the publication in the Journal of Future Oncology titled “A
multivariable model to predict survival for patients with hepatic carcinoma or liver
metastasis receiving radiotherapy” by Jason Vickress, Michael Lock, Simon Lo, Stewart
Gaede, Aaron Leung, Jeff Cao, Rob Barnett, and Slav Yartsev.
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1.11.2 Automatic landmark generation for evaluation of deformable image
registration accuracy (Chapter 3)
DIR has become a pivotal tool in radiation therapy for contour propagation, anatomical
assessment and dose accumulation even though errors are common and poorly
characterized. Different DIR evaluation techniques are used in practice including contour
evaluation and landmark matching but both require significant user input and are difficult
to apply routinely. We developed a method of automatically generating landmarks using
the scale-invariant feature transform and tested it against both amateur and expert
landmark sets. The results of this work were published in the Journal of Physics in
Medicine and Biology titled “Automatic landmark generation for deformable image
registration evaluation for 4D CT images in lung” by Jason Vickress, Jerry Battista, Rob
Barnett, John Morgan, and Slav Yartsev.

1.11.3 Dosimetric impact of deformable image registration error in radiation
therapy (Chapter 4)
DIR has been introduced to track anatomical changes between daily fractions to
accumulate the actual radiation dose. Unfortunately, inherent errors in DIR can lead to
significant changes in dosimetric analysis and need to be accounted for in any analysis. In
this study, we derived a method to incorporate predicted registration uncertainty into the
final dosimetric analysis using expert landmarked lung 4DCT studies. This chapter is
based on the publication in the Journal of Physics in Medicine and Biology titled
“Representing the dosimetric impact of deformable image registration errors” by Jason
Vickress, Jerry Battista, Rob Barnett, and Slav Yartsev.

1.11.4 Daily assessment of dose change using deformable image registration
without dose-recalculation (Chapter 5)
Adaptive radiation therapy has been successful for many treatment sites where anatomical
changes are frequent and can cause the dose distribution to deviate from what was
planned. Currently plan adaptation is triggered by manual evaluations of daily CBCT
images by therapists, physicists and oncologists leading to either plan adaptation or to
continue the original plan. Using DIR and the planned dose distribution an automatic
method for determining the necessity of plan adaptation was developed and tested against
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the gold standard of using a new CT study with a new dose calculation. The results of this
method have been submitted to the Journal of Applied Clinical Medical Physics titled
“Online daily assessment of dose change in head and neck radiotherapy without doserecalculation” by Jason Vickress, Jerry Battista, Rob Barnett, and Slav Yartsev.
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Chapter 2

2

A multivariable model for the prediction of survival for
patients with hepatic carcinoma or liver metastasis
receiving radiotherapy

This chapter has been previously published as “A multivariable model for the prediction
of survival for patients with hepatic carcinoma or liver metastasis receiving radiotherapy”
published in Future Oncology, 13 (1), 19-30 by Jason Vickress, Michael Lock, Stewart
Gaede, Aaron Leung, Jeff Cao, Rob Barnett and Slav Yartsev. Permission to reproduce
this article was provided by the publisher and presented in Appendix A.3. Additional
explanation of clinical tools and parameters is presented in Appendix B.

2.1

Introduction

Liver cancer, as of 2013, has the sixth highest incidence rate with the third worst survival
rate worldwide [1]. Historically, radiation therapy has played a limited role in the
treatment of liver cancer because of the normal liver’s inherent radiosensitivity. However,
studies on the radiobiological effects of radiation on the liver provided the ability to
determine suitable radiation dose levels, and on how to select patients appropriate for
radiation have resulted in an increasingly important role for radiation [2].
The advent of stereotactic body radiotherapy (SBRT) made possible the delivery of high
radiation doses to the target while sufficiently sparing the surrounding healthy tissues,
which is critical for the radiotherapy of liver cancers. Studies have shown significant
benefits to local control and survival [3-7] using more intensive treatments at the cost of
potential toxicity [8,9]. Recently, two comprehensive summaries of the literature have
established the current knowledge on hepatic radiation. Klein et al. reviewed
hepatocellular carcinoma radiotherapy demonstrating a local control rate of 80-90% for
selected patients with smaller tumours and no portal venous thrombosis [10]. This
thorough review also confirms that low rates of adverse events have been found.
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However, the review also confirms the wide variation in treatment technique and patient
selection criteria for radiation. This makes interpretation and comparison of trials
difficult. For example, comparison of trial A that included patients with a better outcome
than trial B would result in the inappropriate conclusion that trial A treatment technique
was better. Nomograms and risk stratification play an important role in allowing a
comparison of study outcomes and selection of the most appropriate patients for future
trials.
For metastatic disease, a similar review performed by Hoyer et al. plus an international
survey demonstrated similar results and made similar recommendations to the
hepatocellular review. For metastatic lesions, 1-year local control rates ranged widely
from 23% to 95% likely due to a lack of consensus on the selection of patients [11, 12].
Despite multiple well-performed studies, radiation is not included in many of the major
guidelines used to treat liver lesions [13]. Why is this? First, large-scale multicentre trials
in this patient group have not been performed despite being a cancer with one of the
highest death rates and a research priority. Trial accrual is often difficult due to the rapid
progression of the disease, variability in treatment availability and the patient’s reluctance
to be randomized to a treatment arm with a known poor outcome or one with evidence
collected primarily from relatively small case series. Second, treatment-related factors
have not been properly established. Therefore, individual centres are performing liver
radiation using a wide variety of strategies especially variable doses, fractionation and
patient selection [12]. Third, the patient population is very heterogeneous with respect to
presentation, previous treatments, the extent of disease, and location of disease requiring
larger sample sizes. A larger number of patients need to be investigated to be able to
statistically reveal important information from such a heterogeneous population. Lastly,
current analyses have not always accessed the vast amount of physics and dosimetric data
available and have previously focused on clinical and imaging parameters, such as alphafetoprotein (AFP) or tumour size. Furthermore, patient numbers in individual centres are
insufficient to provide the higher number of data points required to assess the potentially
numerous critical parameters such as appropriate dose [14].
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To address these factors, our ability to properly combine and analyze data collected from
multiple institutions is critical; this will lead to practical treatment strategies based on
information from comparable groups and clinical trials where outcomes can be assessed
as better or worse than previously published trials. The use of a predictive tool will assist
in standardizing patient selection based on risk group, thereby providing a greater ability
to accrue to multicenter trials and compare outcomes. This methodology may also
promote the inclusion of physics and dosimetric parameters not usually included in
nomograms. Finally, a tool to provide consistent outcome data in this heterogeneous
population will provide information a) on which patients may benefit from radiotherapy
to referring physicians, and b) for administrators, clinical trialists and guideline
developers on the expected outcome of patients receiving radiation.
Using large collections of patient data, clinical models of survival and recurrence have
been successfully developed for multiple treatment sites in radiation therapy [15, 16],
including liver cancer [17]. In this publication, we develop a multivariable prognostic
model for predicting overall survival after radiation therapy for patients with primary and
metastatic liver cancer based on data from one of the largest published liver databases as
proof of principle of this methodology.

2.2

Methods

2.2.1

Patient population

The patient population consisted of 195 patients receiving radiation treatment for
hepatocellular carcinoma (HCC) or liver metastasis (Mets) in a comprehensive tertiary
cancer facility from 2004 to 2015, with demographics shown in Table 2-1. Patients were
considered for the study if they were ineligible for standard treatment (TACE, surgery or
RFA) and received radiation treatment, but were excluded if they received low dose
palliative treatment. Sorafenib was the principle chemotherapy provided. However, many
of the patients were entered into trial prior to the release of sorafenib. Therefore,
chemotherapy included the previous standard which was doxorubicin. Study endpoints,
such as overall survival (OS) and disease-free survival (DFS), were collected from patient
charts and electronic records. All data collection and analysis was approved by the local
ethics board.
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Table 2-1: Patient demographics
Characteristic

HCC (N = 66)

Mets (N = 129)

70 ± 12

65 ± 12

56 (85%)
10 (15%)
384±447

67 (52%)
62 (48%)
351±870

45 (68%)
7 (11%)
10 (15%)
4 (6%)

65 (50%)
32 (25%)
19 (15%)
13 (10%)

42 (64%)
22 (33%)

99 (77%)
28 (22%)

2 (3%)
0 (0%)

2 (1.5%)
2 (1.5%)

Bilirubin
Serum Albumin

21.6±29
35±6

17±32.7
38±6

Ascites
Y

19 (29%)

12 (9%)

47 (71%)

117 (91%)

Age (years)
Sex
Male
Female
tumour volume (cm3)
# of lesions
1
2
3
>3
CP Grade
A
B
C
unknown

N
primary site (N = 130)
colorectal carcinoma
cholangiocarcinoma

52 (40%)
22 (17%)

neuroendocrine carcinoma
breast carcinoma

10 (8%)
10 (8%)

non-small cell lung carcinoma
pancreatic carcinoma
renal cell carcinoma
metastatic melanoma
gastric carcinoma
esophageal

10 (8%)
7 (5%)
3 (2%)
3 (2%)
3 (2%)
3 (2%)

other
previous treatments
chemo embolization
I-131 lipiodal
radiofrequency ablation
chemotherapy
liver resection
previous abdomen radiation

6 (4%)
17 (26%)
7 (11%)

7 (5%)
6 (5%)

3 (5%)
6 (9%)
5 (8%)
0

9 (7%)
95 (74%)
32 (25%)
9 (7%)

HCC - hepatocellular carcinoma, Mets - metastatic disease, CP- Child-Pugh
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2.2.2

Radiation treatment

Patients received radiation treatment using Volumetric Modulated Arc Therapy (VMAT),
fixed beam Intensity Modulated Radiation Therapy (IMRT), three-dimensional conformal
radiotherapy (3DCRT), or helical Tomotherapy (Tomo). Radiation dose prescriptions
varied between 15 and 88 Gy in 5 to 35 fractions using a radiobiologically-guided
prescription program similar to the radiobiological NTCP dose calculation published by
Dawson [18, 19]. Patients receiving 5 or 6 fractions were irradiated every other day, and
the remaining patients were treated daily for 10-35 fractions. Most patients were treated
using a respiratory gated and image-guided technique. The remainder of patients, who
were either unable to hold their breath or had irregular breathing, were treated with full
respiratory motion using a complete internal target volume (ITV). Gross tumour volume
(GTV) delineation was performed on the primary planning contrast-enhanced 4DCT
images.

2.2.3

Statistical analysis

The effect of each variable on OS was evaluated using the Cox proportional hazards
model. Continuous variables entered into the model were biologically effective dose to
the tumour (α/β = 10 Gy) in 2 Gy fractions (EQD2), volume of normal liver receiving
more than 24 Gy total dose (V24), GTV, bilirubin count, serum albumin, prothrombin,
Child-Pugh (CP) score and age. Dichotomous variables; ascites, prior chemotherapy, and
colorectal primary disease, were assigned values of 0 or 1. Hepatic encephalopathy was
not entered into the model because only 3 patients exhibited symptoms. For univariate
analysis, patients were stratified into several subgroups based on (i) liver function (CP A
vs CP B+C) and (ii) primary HCC vs metastasis (Mets). Hazard ratios (HR) were defined
by dividing the partial hazard of the third quartile by the first quartile to get an effect
across the spectrum of clinical values.
Identification of the most useful variables was performed with univariate Cox
proportional hazard modelling, followed by multivariable analysis performed using a
stepwise selection with a significance level of 0.05. Once the most significant variables
were identified, nomograms predicting OS at one year were assembled for both HCC and
Mets subgroups. Nomograms were evaluated by a concordance index (C-index) [20]
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using four-fold cross-validation with 200 iterations to reduce bias. The C-index measures
the discrimination of the data and the values range from 0.5 (no discrimination) to 1.0
(perfect discrimination). Model calibration was performed by grouping patients according
to their nomogram-predicted probabilities and comparing them against the observed
Kaplan Meir Overall Survival estimate, presented as calibration curves. The goodness of
fit of the calibration curves are evaluated by the Hosmer-Lemeshow (HL) test, with a
value greater than 0.05 having a strong fit.

2.3

Results

2.3.1

Patient demographics

The heterogeneous patient population used in this study allowed us to investigate the
effect of a large number of parameters on the outcome of radiation therapy (Table 2-1).
The majority of patients had liver metastases (n = 129), but the number of patients with
primary HCC (n = 66) was still sufficient for statistical comparison.

Because of

developing technologies within 2004-2015, the radiation treatment techniques evolved
from 3DCRT (n = 58) to IMRT (n = 68), to VMAT (n = 62) and Tomo (n=7). The
prescribed planning tumour volume (PTV) doses had a wide range of 15 – 88 Gy (median
45 Gy). Treatment schedules were either treated every other day for 5-6 fractions (58% of
patients) or daily treatment for 10-35 fractions (42% of patients). Patients had varying
liver functions with CP scores ranging from 5 to 10 (median 6). The overall survival for
patients with HCC or liver metastasis is described by the Kaplan Meir curve in Figure 2-1
with 12/66 and 33/129 missing events for HCC and liver metastasis groups respectively
with a median follow up of 37 months.
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Figure 2-1: Kaplan--Meir survival curves for patients with HCC and secondary liver metastasis.

2.3.2

Effect of liver function

To investigate the impact of liver function before radiation treatment, patients were
stratified into two groups based on their overall pre-treatment liver function, as defined by
CP score A vs score B+C. Cox regression analysis was performed on both patient groups
and the effect of radiation treatment parameters and liver function on OS is shown in
Table 2-2. For patients with a CP score A, increased radiation dose (EQD2) showed a
significant survival benefit. In both CP A and CP B+C groups, poor liver function
parameters (CP Score and Serum Albumin) and larger GTV size had a negative effect on
overall survival.
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Table 2-2: Univariate Cox regression analysis of two CP score groups for OS.
CP-A

CP B/C

Factor

HR

95% CI

p-value

HR

95% CI

p-value

GTV
EQD2Gy
V24
Bilirubin
Serum Albumin
Ascites
Prothrombin
CP Score
Age
# of Lesions
Extrahepatic
Chemo

1.18
0.61
0.94
1.14
0.54
1.34
1.22
2.65
1.06
0.92
1.33
0.95

1.03 - 1.34
0.46 - 0.8
0.70 - 1.25
0.87 - 1.5
0.37 - 0.79
0.58 - 3.08
0.92 - 1.61
1.18 - 5.97
0.84 - 1.35
0.79 – 1.08
0.91 – 1.95
0.65 - 1.39

0.014
< 0.001
0.654
0.326
0.001
0.487
0.167
0.018
0.617
0.33
0.14
0.795

1.19
0.84
1.20
1.12
0.41
1.54
0.87
3.95
0.77
0.91
1.63
0.82

1.07 - 1.32
0.49 - 1.45
0.81 - 1.79
1.06 - 1.18
0.27 - 0.63
0.84 - 2.82
0.74 - 1.02
2.02 - 7.75
0.48 - 1.21
0.74 – 1.11
0.89 – 2.98
0.45 - 1.51

0.001
0.538
0.366
< 0.001
< 0.001
0.160
0.080
< 0.001
0.252
0.35
0.11
0.532

GTV – gross tumour volume, EQD2Gy – equivalent dose in 2 Gy fractions, V24 – the volume of normal liver receiving
24
Gy
CP – child pugh

2.3.3

Primary HCC vs liver metastasis

Based on our analysis, two nomograms were constructed for the OS of patients treated for
a primary HCC (n = 66) or liver metastasis (n = 129). The results of the univariate
variable selection and multivariate modelling are presented in Table 2-3. The final model
variables are presented in the multivariable columns of Table 2-3, with the full model
described in Table 2-4.
Table 2-3: Univariate and multivariable Cox regression results for both HCC and metastasis.
HCC
Univariate
Factor
GTV
EQD2Gy
V24
Bilirubin
Serum
Albumin
Ascites
Prothrombin
CP Score
Age

Multivariate

HR
1.68
0.51
1.28
1.34

95% CI
1.3 - 2.17
0.34 - 0.78
0.9 - 1.81
1.15 - 1.56

p value
< 0.001
< 0.001
0.17
< 0.001

HR
1.81

95% CI
1.42 - 2.32

p value
0.001

1.31

1.11 - 1.55

0.001

0.39
2.18
0.95
2.25
1.01

0.25 - 0.62
1.16 - 4.09
0.81 - 1.12
1.49 - 3.41
0.74 - 1.39

< 0.001
0.02
0.55
< 0.001
0.93

0.39

0.23 - 0.67

< 0.001
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# of Lesions
Extrahepatic
Chemotherapy

1.10
1.00
1.00

0.84 - 1.45
0.45 - 1.69
0.34 - 2.25

0.48
0.69
0.78
Metastasis

Univariate
Factor

Multivariate

GTV

HR
1.12

95% CI
1.05 - 1.19

p value
< 0.001

HR
1.07

95% CI
1 - 1.14

p value
0.04

EQD2Gy
V24

0.66
0.86

0.5 - 0.87
0.61 - 1.22

< 0.001
0.40

Bilirubin
Serum
Albumin
Ascites
Prothrombin
CP Score
Age
# of Lesions
Extrahepatic
Chemotherapy
Colorectal

1.15

1.1 - 1.2

< 0.001

1.11

1.06 - 1.17

< 0.001

0.43
1.00
1.04
1.64
1.08
0.87
1.79
0.90
0.67

0.31 - 0.58
1-1
0.97 - 1.12
1.35 - 1.99
0.83 - 1.39
0.77 - 1.04
1.18 - 2.71
0.58 - 1.4
0.44 - 1.01

< 0.001
0.01
0.29
< 0.001
0.57
0.16
0.01
0.64
0.01

0.49

0.36 - 0.68

< 0.001

0.62

0.4 - 0.96

0.03

GTV – gross tumour volume, EQD2Gy – equivalent dose in 2 Gy fractions, V24 – the volume of normal liver receiving
24 Gy, CP – child pugh

Table 2-4: Model results including β values, units and 6 months / 1-year baseline cumulative hazard
ratio.
HCC Model
Variable

Units

β

6 month λ0

1 year λ0

Bilirubin count
Serum Albumin

mg/dl
mg/dl

0.0203
-0.104

5.91

11.80

6 month λ0

1 year λ0

11.83

23.07

GTV

cm3
0.00131
Metastasis Model

Variable

Units

Beta

Bilirubin count
Serum Albumin
Colorectal primary site

mg/dl
mg/dl
yes (1), no (0)

0.0154
-0.0889
-0.4774

GTV
cm3
0.000296
λ0 indicates cumulative baseline hazard ratio, GTV – gross tumour volume
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The nomogram predicting OS at six months and at one year for patients with a primary
HCC is displayed in Figure 2-2a. The greatest effect on the patient’s survival is predicted
by liver function parameters (bilirubin and serum albumin). Similar trends are found in
the nomogram for metastases in Figure 2-2b, with a lower overall survival than HCC.
For model evaluation, the concordance values were found to be 0.74 for the HCC model
and 0.68 for the metastasis group after four-fold cross-validation, performed 200 times
showing good discrimination.

Figure 2-2: Nomogram for the probability of six months and one-year survival for patients with (a)
HCC and (b) liver metastasis.

The calibration curves for both models are shown in Figures 2-3 and 2-4 (with the result
of the HL test) for the HCC and metastasis models respectively. Calibration curves
yielded good calibration abilities for both six months and one-year survival for the HCC
model (Figures 2-3a and 2-4a) and the Mets model (Figures 2-3b and 2-4b).
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Figure 2-3: Kaplan--Meir survival curves for HCC (a) and Mets (b) showing the lower (solid) and
higher (dashed) risk groups obtained by the multivariate models.

Figure 2-4: Calibration curves for predicting 6-month survival for HCC (a) and Mets (b). The
goodness of fit was calculated using the HL test yielding a p-value of 0.1693 and 0.0412 for HCC and
Mets respectively.

Kaplan Meir curves between high and low-risk patients (as determined by the model
separated by the median hazard ratio) presented in Figure 2-5, showed significant
separation for both the HCC and Mets models.
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Figure 2-5: Calibration curves for predicting 1-year survival for HCC (a) and Mets (b). The goodness
of fit was calculated using the HL test yielding a p-value of 0.211 and 0.077 for HCC and Mets
respectively.

2.4

Discussion

2.4.1

Patient demographics

Liver cancer affects a wide range of patients with different underlying pathologies,
treated with different treatment strategies and with varied functional status creating a very
heterogeneous patient population that is typically seen in the literature. Though
heterogeneous patient data causes problems with generalizability and requires large
sample sizes to determine predictive variables; when we have sufficient patient numbers,
heterogeneous treatment data provides an opportunity to clarify questions such as what
dose should be prescribed as many different prescriptions are used in clinics.
Heterogeneous data in this study enabled the analysis of HCC and metastasis patients
with different liver functions (CP-A, or B+C) in one of the largest published datasets in
the literature. This dataset included varying dose prescriptions (20 to 70 Gy), and
fractionations (5 to 25 fractions), which created different biological effective doses and
allowed for the analysis of the benefits of different dose prescriptions.
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2.4.2

Liver function

A patient’s liver function before the start of radiation therapy is known to be a strong
predictor of OS [21]. The analysis from the Cox regression for OS shows a significant
difference between patients with a Child-Pugh score of A vs B+C. Patients with CP A
had a significant survival advantage with increased radiation dose to a tumour, whereas
patients with grade B+C did not. Previous work on patients with CP B+C has shown
similar results regarding the poor response to radiation therapy [21], with similar effects
from tumour size and CP score. Increased CP score post radiation therapy has also been
shown as a strong predictor of overall survival [22]. Poor liver function and large tumour
size correlated with decreased survival in all cases. However, only patients with better
liver function showed a significant increase in survival due to higher radiation dose.
Therefore, these data suggest that if patients have a poor liver function (defined as CP
B+C), clinicians would provide better care by not dose escalating and unnecessarily
risking toxicity. For those with good liver function, dose escalation is an important factor
for improved survival. Further research is required to determine the appropriate dose.

2.4.3

Nomogram

The nomogram in Figure 2-2a for patients with HCC describes the effect of liver function
and tumour size as major factors in determining patient survival. The nomogram
demonstrates that liver function and tumour size are much more significant compared to
an increase in radiation dose. With an average C-index of 0.74, which is substantial given
the heterogeneous nature of the dataset the model for HCC is accurate in predicting OS.
For example, the six months and one year OS probability would be 28% and 9%,
respectively for an HCC patient with a bilirubin count of 40 mg/dl, serum albumin 30
g/dl, GTV volume of 500 cm3. For a patient with a bilirubin count of 30 mg/dl, serum
albumin 30 g/dl and GTV volume of 300 cm3 six months and one year OS would be 50%
and 26%. After reviewing models predicting OS for HCC patients after non-radiation
treatments, this radiotherapy nomogram falls within a similar C-index range with
chemoembolization 0.84 [23], immunotherapy 0.698 [24] and liver resection surgery 0.66
[25]. All these models share the same large weightings on the patient’s liver function pretreatment. Our model also has similar results to the prognostic score ALBI (validated on a
larger cohort of 2599 patients) [26] demonstrating the significance of Serum Albumin and
47

Bilirubin in predicting overall survival for HCC patients, without the other factors in the
Child-Pugh score. We are unaware of any nomograms for liver cancer radiotherapy and
believe our model is the first to be created for patients receiving radiation therapy for
hepatocellular carcinoma.
The metastasis model in Figure 2-2b with an average C-index of 0.68 is less accurate than
the HCC model which is expected given the more complex and heterogeneous nature of
the metastatic disease. This fact is further emphasized from the HL test on the calibration
curves with values close to 0.05 showing a worse fit than for the HCC model. Our
analysis showed that increased radiation dose is not a significant factor in predicting
patient survival. A previous study [27] has created a nomogram predicting OS for liver
metastasis with an area under the curve (AUC) value of 0.83, but it included different
liver parameters and had no treatment information. The trial focused on a select and
relatively homogenous subpopulation of liver metastases with external validation. The
trial assessed only the subpopulation of colorectal patients treated with selective internal
radiation therapy. Our model is more generalizable and attempts to include a broader
range of parameters. In particular, the effect of treatment parameters, especially
prescription dose, to help determine when aggressive treatment is warranted and what the
patient prognosis may be with radiation. We believe our nomogram is the first to be
created for liver metastases patients treated with external beam radiation.

2.4.4

Potential limitations

Although our model was shown to have comparable accuracy to other models created for
the treatment of liver malignancies, the heterogeneity of the data results in decreased
accuracy and ability to address specific subgroups. Therefore, despite being based on one
of the largest published databases, this model would benefit from more data. Data accrued
from multiple centres using different dose regimens and constraints would provide the
heterogeneity in data and sufficient sample size required for detailed analysis of
subgroups. Using patient sample sizes of 66 for HCC and 129 for Mets can create useful
models for predicting survival using only four variables. However, there may be other
undiscovered variables that could improve the predictive ability of these models. With
larger sample sizes, we can also develop nomograms for specific subgroup such as
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cholangiocarcinomas or those patients heavily pretreated prior to radiation versus those
referred early in their natural history. In this model, they are grouped together within the
Mets group. Validation was successfully performed using a four-fold cross-validation,
performed in 200 different random combinations, but external validation with a different
data set is recommended. Determining the true accuracy of this model will require
external validation, from an equivalent population of HCC and Mets patients, which is an
aim for future work since the c-indexes for both models are likely to be lower in a
validation set.

2.5

Conclusion

Two models in the form of practical nomograms were constructed for HCC and liver
metastasis patients to help predict overall survival. The nomograms may help clinicians
better select appropriate treatment strategies and provide prognostic information for
patients. The nomograms provide more practical and effective use of available data from
patients treated for liver cancer. Our conclusion that dose escalation is beneficial only for
patients with good liver function (CP score A) but not CP B+C patients is also useful
clinical information. Overall this study presents new tools for the selection of appropriate
treatment options for patients diagnosed with liver malignancies.
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Chapter 3

3

Automatic landmark generation for deformable image
registration evaluation for 4D CT images of lung

This chapter has been previously published as “Automatic landmark generation for
deformable image registration evaluation for 4D CT images of lung” published in the
journal Physics in Medicine and Biology, 61(20), 7236 by Jason Vickress, Jerry Battista,
Rob Barnett, John Morgan and Slav Yartsev. Permission to reproduce this article was
provided by the publisher and presented in Appendix A.4. Additional details about the
Scale Invariant Feature Transform (SIFT) is presented in Appendix C.

3.1

Introduction

Medical imaging has become a large focus in health care across both fields of diagnosis
and therapy. Extensive longitudinal imaging studies require reliable and accurate image
registration for scientific analysis. In diagnostic applications, changes in tissue
distribution over time helps assess the progression or regression of disease prior to and
following treatment. Another example is the need to track radiation dose accumulation
quantitatively across a multi-fraction treatment where sharp dose gradients transform
small geometric displacements into potentially large dose errors in the cumulative dose.
With advancements in computing, many image registration algorithms and software
platforms have been developed to perform such tasks. Unfortunately, each commercial
product has hidden features and variable performance creating registration inaccuracies
which impact the quality of any geometric or dosimetric analysis [1, 2]. In modern
clinical practice, simple rigid registration methods are being replaced by more
sophisticated deformable image registration (DIR) creating a large demand for reliable
evaluation techniques that assess the accuracy of the deformation field and its effect on
the radiation dose distribution.
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Evaluation of image registration methods is difficult since it requires a “ground truth”
benchmark derived from biophysical modelling, mechanical phantoms or landmark sets
established by expert interpretation of paired images. The landmark method is currently
the most popular, but it is very time-consuming as indicated in a study by Castillo et al.
[3] where an average of 12 hours per computed tomography (CT) study was required to
create high-quality landmarks in the lung. Another important factor is the accuracy or
appropriateness of the landmark which can be limited by observer bias and/or poor image
quality.
Many methods that locate landmark pairs between images automatically have been
developed [4, 5] with the most promising results from the Scale Invariant Feature
Transform (SIFT) algorithm [6]. Although SIFT algorithms have been shown to
accurately locate landmarks in 2D images they have been less successful for 3D medical
image studies [7]. Some of these problems include matching similar, non-unique
landmarks and localization of the specific points within the 3D image space. Even with
demonstrated improvements in the accuracy of SIFT [8, 9], limitations persist, especially
in crossing imaging modalities such as matching diagnostic CT and cone-beam CT
images acquired on radiotherapy machines.

To improve both the resource-intensive

nature of manual landmark selection and SIFT pitfalls and limitations, we present a
hybrid solution involving straightforward manual editing of results obtained initially by a
rapid SIFT algorithm. As DIR becomes more popular in the field of clinical evaluation,
quality assurance, and “big data” mining, validation techniques need to be developed to
ensure that matching landmarks are truly homologous and located correctly. Automatic
landmark creation approach is an attractive option for DIR and its evaluation [10] if it is
shown to have comparable accuracy and usability to manual landmarks. In this study, we
compare an automatic landmark method to conventional manual landmarking, and high
quality (gold standard) landmark sets to demonstrate that automated algorithms can
replace manual landmarks for the validation of DIR. An example using 4DCT datasets of
the lung at different respiration phases is used to illustrate the principles and advantages.
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3.2

Methods

Ten thoracic 4DCT studies were obtained from the “dir-labs” group (http://www.dirlab.com/) for use in this study. Three methods of landmark selection on the 0% and 50%
phases of respiration were tested: manual, SIFT, and SIFT with manual correction (SIFTM). Each landmarking method was compared to a landmark set produced by the dir-labs
group for these images, which was considered as the gold standard (GS), having been
validated in multiple publications [3]. The GS landmark set contained 300 landmark pairs
manually selected between the 0% and 50% respiratory phases.

3.2.1

Manual

An in-house software tool was created in MATLAB® (version r2015a, MathWorks) to
facilitate manual landmark selection and matching across both phases of a 4DCT study
(0% and 50% phases). The tool allows users to search through slice images and, after
applying a pre-defined window and level, to locate unique matching pairs of anatomical
points across both images. Two landmark sets were created independently by two
observers, to mitigate effects of observer bias. Three rules were outlined for the selection
and definition of unique landmark pairs: (1) pairs must be at unique locations in three
dimensional spaces, (2) pairs must be surrounded by lung parenchyma tissue and not be
near or defined by an edge, (3) a unique CT feature can only be landmarked once. For
practical reasons, each observer was limited to a maximum of 300 landmarks per 4DCT
study, and four hours of work per study.

3.2.2

SIFT

Automatic landmark selection was performed using a modified version of the SIFT
algorithm based on the original work of Lowe [6] for 2D images, starting with a double
size image with three octaves each having three levels per octave. We adapted the SIFT
algorithm to 3D medical CT images using the methods suggested by Allaire et al. [8] not
including full landmark re-orientation. Specific parameters selected for the algorithm
included σ = 1.1 for the Gaussian scaling, Hmax = 7 for edge removal, rthresh = 0.01 for
contrast selection. Parameter selection was based on the work of Allaire et al., with minor
modifications to improve landmark selection for the lung 4DCT studies.
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Keypoint descriptors were made of 4×4×4 subgroups each containing a 2D angular
histogram with 8 azimuthal directions (between 0 and 360 degrees) and 4 elevation
directions (between 0 and 180 degrees) creating a 2,048 element array. Matching a keypoint in the initial image is performed by finding a key-point in the final image that has
the lowest Euclidian descriptor distance calculated as the distance between two 2,048
element vectors. A pair is considered unique if the second most similar point (second
lowest Euclidian distance) has a Euclidian distance 1.66 times larger than the most similar
point (lowest Euclidian descriptor distance). All computation was performed on a 3.7
GHz quad-core processor running a single-threaded program in MATLAB®. To reduce
computation time and memory limitation, landmarking was only performed within the
lung region.

3.2.3

SIFT-manual hybrid

The hybrid approach selects landmarks initially identified by the SIFT algorithm as
previously described followed by a review of each landmark pair. Each landmark pair
was presented to the reviewer (located in the axial plane of the image) and accepted or
rejected based on visual similarity. The visual similarity criterion involves a quick
evaluation of each landmark, to determine if they are both located in the same region of
the image. An example of a rejected landmark pair is shown in Figure 3-1, where it is
clear that the landmarks are in different slices of the image study. All landmark reviews
were performed before any analysis took place, making the reviewer blind to true
erroneous landmarks.

Figure 3-1: Example of an excluded landmark pair (crosses) produced from SIFT. The pair was
excluded because the landmarks were located in different slices of the CT study.
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3.2.4

Landmark displacement evaluation

The accuracy of each method was determined by comparison of the generated landmarks
to the GS landmark set using two metrics: the mean (global) landmark displacement and
proximal (local) landmark displacement.
Mean landmark displacement was calculated as the mean displacement for all landmarks
within a structure and was compared to the mean displacement of the gold standard
landmark set within the same structure. Such evaluation provides a global sense of
magnitude agreement between displacement vectors. The structures of interest were the
left and right lungs separately, creating 20 test cases in total for all ten 4DCT studies. The
final results were evaluated by an Intra Class Correlation (ICC) test between each
landmarking method and the GS across all 20 lung structures.
Proximal landmark evaluation was introduced to compare the displacement of a test
landmark pair to the displacement of the closest GS landmark pair. To find a proximal
landmark pair a test landmark pair is first selected, then a GS landmark pair is located that
has the shortest Euclidian distance between their initial positions in the 0%-phase image
study. Figure 3-2 illustrates the proximal landmark selection with GS1 being selected as
the proximal landmark pair because of d1 < d2. Then using the deformation vector field
produced from the DIR, the approximate magnitude of deformation for the test and
closest GS landmark is determined. If the difference in magnitude of deformation
(|

|−|

| from Figure 3-2) is greater than the smallest voxel dimension the test

landmark pair is excluded. This final criterion is required to ensure that the proximal
landmark initial positions are similar enough for direct comparison. The result is a set of
test landmark pairs with the corresponding proximal GS landmark pairs. The landmark
displacements in both sets were compared using an ICC.
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Figure 3-2: Proximal landmark selection with landmarks in the 0% phase (circles) and 50% phase
(squares) from the test (white) and gold standard (black) landmark sets including; landmark
displacement D, DIR predicted landmark displacement DDIR, distance between 0% positions d and
DIR error ε for a test landmark T, and two GS landmarks 1 and 2.

3.2.5

Deformable image registration evaluation

The DIR error was calculated by the algorithm from MIM software (version 6.5
MIMVista) for each landmark as the Euclidian distance between the DIR predicted and
actual positions of the landmark in the 50% phase shown as ε in Figure 3-2. The
evaluation of DIR error was done for the manual, SIFT, SIFT-M and GS landmark sets
using mean DIR error and proximal DIR error metrics. These two metrics were defined
by the same method as the mean and proximal displacements but using the DIR error for
each landmark pair (ε), instead of the landmark displacement (D).

3.3

Results

Both observers 1 and 2 were able to select 300 landmarks in each CT study pair (0% and
50% phases) taking 1100 and 1700 minutes, respectively, resulting in an average
generation time per landmark pair of 22 and 34 seconds. The SIFT algorithm produced on
average 128 landmarks per study and the SIFT-M method produced on average 120
landmarks per study. To normalize for different lung volumes, the number of landmarks
per study was divided by the total lung volume determined from manual lung contours,
resulting in landmarks per litre values are shown in Figure 3-3. The calculation time for
SIFT was 47 minutes for all 10 studies, yielding an average time per landmark of 2.3
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seconds. The hybrid SIFT-M method excluded on average 8 landmarks per study, with
most rejected landmarks located in regions of distorted image contrast caused by motion
artifacts. The landmark review by the SIFT-M method took on average 3.3±1.2 minutes
per study, resulting in an overall average time of 4.1 seconds per landmark.

Figure 3-3: Number of landmark pairs per litre located using SIFT and SIFT-M landmark creation
methods for 10 4DCT studies. The SIFT-M method excludes some of the SIFT points using visual
inspection.

3.3.1

Mean displacement

Comparison of the mean lung displacement for manual landmarks versus GS is shown in
Figure 3-4a with an ICC value of 0.86 for both observers. The SIFT algorithm’s mean
lung displacement is compared to the GS method in Figure 3-4b, with an ICC value of
0.85, and the results for the SIFT-M method were similar (shown in Figure 3-4b) with an
ICC of 0.82.

59

Figure 3-4: Mean lung deformations for 20 lungs: a) Observers 1 and 2 vs GS and b) SIFT and SIFTM methods vs GS. The black line shows ideal agreement.

3.3.2

Proximal deformation

The proximal deformation comparison between manual landmarks and GS gave an ICC
of 0.97 and 0.98 for observer 1 and 2 respectively. When compared to the GS, the SIFT
algorithm had an ICC value of 0.91 with the results from all ten studies presented in
Figure 3-5a. With the removal of visually dissimilar landmarks using SIFT-M, the results
became much more reliable (Figure 3-5b) with an ICC of 0.96.
The summary of landmark comparisons is presented in Table 1.

Figure 3-5: Landmark displacement for proximal pairs for a) SIFT vs GS and b) SIFT-M vs GS for
all ten studies.
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3.3.3

Deformable image registration evaluation

For the mean DIR error (per lung) the accuracy varied significantly between manual and
SIFT methods with ICC values of 0.97, 0.89 and 0.65 for observer 1, observer 2 and
SIFT-M, respectively. For the proximal DIR error, the ICC values were 0.94, 0.96 and
0.90 for observer 1, observer 2 and SIFT-M respectively. The results for DIR error and
landmark displacement for both proximal and mean methods are shown in Table 1 along
with the 95% confidence intervals, across both users, SIFT and SIFT-M techniques.
Table 3-1: ICC values and corresponding 95% confidence intervals for DIR error and landmark
displacement for both mean and proximal methods.
Proximal
displacement

Mean Lung
displacement

Proximal DIR
Error

Mean DIR Error

SIFT

0.91 (0.90-0.92)

0.84 (0.67-0.94)

0.80 (0.77-0.82)

0.72 (0.43-0.88)

SIFT M

0.96 (0.96-0.97)

0.82 (0.61-0.93)

0.90 (0.89-0.92)

0.65 (0.30-0.84)

Observer 1

0.97 (0.97-0.97)

0.86 (0.69-0.94)

0.94 (0.94-0.95)

0.97 (0.93-0.99)

Observer 2

0.98 (0.98-0.98)

0.86 (0.69-0.94)

0.96(0.95-0.96)

0.89 (0.76-0.96)

3.4

Discussion

Producing a landmark set on medical image studies for the purpose of DIR evaluation is a
laborious and tedious task that can take several hours for even the most experienced
individual. Automatic landmarking tools are very attractive if they can provide a reliable
set of landmarks to properly evaluate a deformation vector field produced by a
commercial DIR algorithm. In this study, we have shown a possibility of a six-fold
reduction in time required. With optimization using parallel computing a further reduction
by 20 times compared with purely manual methods appears feasible. In the future,
automatic landmark placement could make near-real-time DIR evaluation a reality,
providing users with more confidence in the quality of their DIR, whenever it is used.
One of the biggest issues with automatic landmarking is producing a sufficient number of
relevant landmarks throughout the image space. In this study we limited the location of
landmarks within the left and right lungs, obtaining 128 landmarks per study using SIFT,
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compared to the 300 landmarks per study used in the gold standard. The number of
landmarks per image varies drastically between images due to the difference in image
quality as shown by the low landmark count per litre in studies #5 and #6 (Figure 3-2)
which exhibited the worst CT image quality.
Too few landmarks per structure can significantly alter the regional analysis of
deformation and DIR error as demonstrated by the lower correlation between GS and
SIFT for mean displacement and mean DIR error compared to the proximal values. This
relatively low correlation for mean lung deformation values was also present when
comparing GS landmark pairs to the ones selected by each observer, demonstrating that
even 300 landmarks were not sufficient to effectively represent the overall range of
deformation in both lungs. The distribution of landmarks can significantly affect any
regional analysis, especially in structures exhibiting a large amount of deformation or
points lying in high dose gradients for dose accumulation studies. Study #8 had the
largest lung deformation and the largest discrepancy in mean lung deformation from the
GS as shown by the largest outlier in Figure 3-4. Higher quality images allow for a more
reliable identification (both automatically and manually) of a greater number of unique
landmark pairs per study. For example, study #3 had superior image quality and fewer
motion artifacts than study #6, resulting in twice as many landmarks located per litre of
lung tissue.
Apart from investigating global deformation properties of an entire structure, another
important factor in deformation analysis is the accuracy of each individual landmark pair
in describing the local deformation. Landmarks created by different methods or observers
very rarely lie on the same point, making it practically impossible to directly compare two
landmark pairs and their impact on evaluating a specific DIR algorithm. Currently,
landmark evaluation is done with manual inspection of each landmark, to determine the
mismatch [7, 4]. In this study, we proposed a new method of comparing landmarks pairs
that are in close proximity. Using this method to compare the landmark displacement
between SIFT-M and the GS yielded an ICC greater than 0.95. Even with the added
uncertainty of evaluating only proximal landmark pairs between each method and the GS,
the reliability of the new landmark sets was maintained. Comparison of the two sets of
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measurements was performed using an ICC because it evaluates the relative agreement
between two different landmarking methods. For this reason, these ICC values cannot be
directly compared to other landmarking methods produced from other image sets, because
they could have a different range of landmark displacements.
Aside from the obvious efficiency benefits of automatic landmarking software, there are
often hidden pitfalls from overlooked erroneous landmark pairs. A SIFT algorithm
matches uniquely contrasted regions (i.e. neighbourhood pixel intensities) in image pairs,
but it has difficulty in non-unique regions allowing occasional significant feature
mismatch. In spite of attempts to improve the landmarks by employing several program
iterations and setting different parameters, between 5%-7% erroneous landmarks were
still produced per image. To discard any incorrect landmarks, a simple manual review and
removal process was implemented, improving the ICC value of proximal displacement
from 0.91 to 0.96, while only doubling the time per landmark generation. The manual
review process was performed using 2D images in the axial plane which created a bias in
the landmark selection due to anisotropy but avoided the timely task of manually
inspecting multiple planes. Even with the added landmark review process, the SIFT-M
method was still six times faster than a purely manual approach.
The proximal landmark evaluation has demonstrated that the SIFT method performed
slightly worse than the manual landmark method when compared to the GS baseline set.
Through the quick removal of obvious erroneous landmarks using SIFT-M, the landmark
accuracy was indistinguishable from the performance of manual users. These results
demonstrate that semi-automatic SIFT landmarks can be used as a replacement for
common manual landmarks in the evaluation of DIR. One important caveat is that any
landmarking algorithm can create incorrect landmark pairs, but using a simple “sanity
check” and ergonomic display software, these landmarks can be effectively removed
through visual inspection. In the future, SIFT algorithms could be developed to
incorporate further consistency checks on these landmarks to further reduce user
involvement and correction.
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3.5

Conclusion

Manually selected image landmarks have long been a standard for guiding image
registration but require a large time investment. We provide a practical evaluation method
of automatic landmarks as a replacement for manual landmarks with a six-fold time
reduction. The SIFT-M method was significantly faster and required only minimal posthoc user intervention to achieve comparable accuracy. Therefore, automatic landmarking
methods can provide a standardized method for guiding and evaluating DIR algorithms
without lengthy landmarking sessions. The remaining challenge for both automatic and
manual landmarking methods is the selection of the optimal /sufficient number or spatial
distribution of landmarks to accurately characterize the deformation of a large
heterogeneous structure such as the lung.
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Chapter 4

4

Representing the dosimetric impact of deformable image
registration errors

This chapter has been previously published as “Representing the Dosimetric Impact of
Deformable Image Registration Errors” published in the journal Physics in Medicine and
Biology 62(17) N391 by Jason Vickress, Jerry Battista, Rob Barnett and Slav Yartsev.
Permission to reproduce this article was provided by the publisher and presented in
Appendix A.4.

4.1

Introduction

Deformable image registration (DIR) is becoming a common tool for all image-guided
procedures including radiation therapy, making it possible to track changes in a patient’s
anatomy using longitudinal image studies. Cumulative dose calculation across multiple
fractions has been introduced for a number of treatment sites including cervical [1-3] and
prostate [4] cancer. The result of a DIR is a deformation vector field (DVF) which maps
every point between pairs of images and may be used to accumulate dose in a reference
image. The veracity of DIR dose accumulation depends on the accuracy of the DVF,
translating registration errors to potentially significant errors in dose.
Improvements in radiation delivery techniques allow for highly conformal treatments
with steep dose gradients. While high dose gradients are attractive to improve patient
outcomes, they may amplify DIR errors into large dose errors. Many vendors of treatment
planning software have produced their own unique algorithms each functioning with
different similarity metrics and regularizers. A range of different DIR results was
demonstrated using 12 algorithms on a deformable pelvic phantom [5] and two
algorithms using a head and neck phantom [6]. Other studies have quantified the DIR
error of various commercial products [7, 8].
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One way of visualizing the impact of DIR error is via the addition of error bounds to a
planned dose volume histogram (DVH) curve, as proposed by Risholm et al. [9] using a
probabilistic registration to account for the DIR uncertainty. From the literature, the
common evaluation of DIR error for commercial algorithms was done by reporting an
expected global DIR error [10-12]. However, clinically it is more important to evaluate
the local dose uncertainty from the DIR error at each point in the image.
Currently, landmarks serve to match point pairs and constitute the most effective method
of local DIR evaluation, measuring the registration error at individual sample voxels
within an image volume. Such landmarks are useful for determining the dosimetric
impact at single voxels, but cannot be used for evaluating the dosimetric impact
throughout an entire image volume since they are limited to a discrete set of voxels. To
fill this role several methods have been developed to predict DIR error in every point of
an image volume, allowing the evaluation of the specific DVF used for dose
accumulation [13-15].
In this study, a set of well-defined landmarked image pairs were used to characterize DIR
error at multiple voxels, with the aim of exploring its dosimetric impact. With the
dosimetric impact determined at each landmark as the gold standard, the effectiveness of
different measures of DIR error can be evaluated and if found promising propagated to
the entire volume. To the best of our knowledge, this is the first study to investigate the
impact of DIR uncertainty on dosimetric analysis using landmarks as reference data.

4.2

Methods

4.2.1

4DCT studies and deformable image registration

Ten thoracic 4DCT images with standardized landmarks were obtained from “dir-lab”
(www.dir-lab.com) [16] and 300 landmarks were provided for each image study pair
matching the end-inspiration and end-expiration phases, matching every point in the endinspiration study with a corresponding point in the end-expiration study. Landmarks were
located across both the left and right lung with no significant bias and were not limited to
only the clinically important regions within the lung. All images were reconstructed
axially with an in-plane resolution between 0.97 mm and 1.16 mm with a matrix size of
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256 × 256 (5 studies) and 512 × 512 (5 studies) and common slice thickness of 2.5 mm.
Actual DIR error was calculated for each landmark pair by calculating the Euclidian
distance between the DIR predicted landmark position in the end-expiration phase and the
actual landmark position. Mean DIR error per study was calculated as the average
landmark error of all 300 landmarks per study. In this work, all DIR procedures were
performed using the standard DIR algorithm within the MIM Maestro software package
(version 6.5 MIM, MIM Software Inc, Cleveland, OH, USA) with no additional refining
of the DVF. Dose distributions were planned on the inspiration phase of each 4DCT study
with standard five-field IMRT plans of a 60 Gy prescription dose to 95% of the planning
target volume (PTV) with maximum doses ranging 69-73 Gy. Each study had a single
target (no nodes) with gross tumour volumes (no ITV) ranging 1 – 43 cm3, with 5 located
in the upper left lobe, 3 in lower left lobe and 2 in the lower right lobe. All dose
calculations were performed on both inspiration and expiration phases using the plan
from the inspiration phase using Pinnacle treatment planning system software version
9.10 (Philips Healthcare, Fitchburg, WI, USA).

4.2.2

DIR error prediction

We investigated three DIR error prediction methods: inverse consistency error (ICE),
transitivity error (TE) and the distance discordance metric (DDM). Each method
produced a value (pm) in millimetres proportional to the DIR error (DE) using the actual
landmark displacement error as the gold standard. DE was calculated by Eq. (1), where k
is the slope and C is a constant (in millimetres) found by the linear regression of the data
from each prediction method vs actual DIR error for all 3000 landmarks in the collection
of ten 4DCT image studies.
=

×

+

(1)

4.2.2.1 Inverse consistency error
The ICE is calculated as the disagreement between the forward and backward DVFs
between the end-inspiration (0%) and end-expiration (50%) phase studies. Calculation of
ICE was done with equation 2 and 3, with the coordinates in the 0% as (x,y,z) and the
forward and backward DVFs as DVF0-50 and DVF50-0 respectively.
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4.2.2.2 Transitivity error
The TE is calculated in a similar manner to the ICE but includes the disagreement
between three DVF’s across three different image studies (the 0%, 30% and 50% image
studies). Calculation of TE was done with equation 4 and 5 with DVF0-30 and DVF30-50
denoting the DVF’s between the 0% and 30%, and 30% and 50% respectively.
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4.2.2.3 Distance discordance metric
The DDM is a simplified version from Saleh et al. [14] using ten phases (0, 10, 20, 30,
40, 50, 60, 70, 80 and 90%) of the 4DCT images to evaluate the DVF between the 0%
and 50% phase. Calculation is performed using equations 7 and 8 shown below where P i
is one of the 8 additional phases (10, 20, 30, 40, 60, 70, 80, 90%) and (x0-50, y0-50, z0-50) is
the position in the 50% from the 0% phase using the DVF0-50.
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The range of dose uncertainty

The range of dose uncertainty (RDU) was calculated for each individual landmark in the
end-inspiration phase as a function of the DIR error and the dose distribution calculated
on the end-expiration phase study. A flowchart describing the process of calculating the
RDU is shown in Figure 4-1, with a corresponding illustration in Figure 4-2. The first
step used the DVF to find the DIR-predicted location of the landmark in the endexpiration phase of the image by adding the corresponding deformation vector to the
initial landmark position in the end-inspiration phase. A sphere of surrounding voxels was
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created around the predicted landmark position in the end-expiration phase, with the
sphere’s radius equal to one of the measures of DIR error for that landmark (2D
illustration in Figure 4-2). Multiple measures of DIR error included (i) the actual DIR
error, (ii) the mean DIR error per study, (iii) ICE, (iv) TE, (v) DDM prediction methods,
(vi) 2 mm, and (vii) 5 mm constant values (representing low and high errors from the
average error of 3.5 ±5.5mm). A spherical sampling volume was created from an
11×11×11 voxel cube with the exclusion of voxels with r > (1.1 × side-length/2). To
accommodate a sphere with a radius equal to the measure of DIR error the cube’s side
length was set at twice this measure. The result is an approximate sampling sphere of 739
voxels with an approximate radius equal to the measure of DIR error. 11×11×11
dimension was selected as a reasonable compromise between a representative number of
voxels and limitations of memory consumption and computation time. A histogram of
dose values throughout the sphere shown in Figure 4-2c was calculated using linear
interpolation from the dose grid values. The RDU in this sphere was defined by the
maximum and minimum dose values within the dose voxel histogram. The RDU was
designed to evaluate the possible doses given the limits of known registration error. The
RDU calculated using the actual DIR error as the radius of the sampling sphere
characterizes the true dose uncertainty which is used to compare with other estimation.

Figure 4-1: Flowchart outlining the calculation of the range of dose uncertainty for a single landmark
starting in the end-inspiration image.
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Figure 4-2: RDU process for a single landmark in end-inspiration phase. The DIR predicted position
of the landmark is located in end-expiration image and dose is sampled in a sphere around it. RDU is
the maximum and minimum doses within the sampling sphere a) end inspiration b) end respiration c)
dose voxel histogram for points within the sampling sphere.

4.2.4

Dose uncertainty evaluation

Evaluation of the calculated dose uncertainty was performed using two methods: the
magnitude of dose uncertainty (MDU) and the inclusion rate (IR). The MDU is simply
the size of the RDU in units of Gy. The MDU was calculated for each individual
landmark in the end-inspiration phase and averaged over all 3000 landmarks across all ten
4DCT studies. Another important characteristic is determining if the actual dose value
lies within the RDU. For an individual study (containing 300 landmarks) the IR is the
percent of landmarks where the actual dose value lies within the RDU “error bars”. The
IR was calculated for each individual study and averaged over all 10 studies. The
sensitivity of the proposed methods was tested using a total of 3000 unique landmarks
experiencing various ranges of deformation error within different local dose distributions.
Both the MDU and IR were calculated for RDUs using each measure of DIR error (actual
DIR error, mean actual DIR error per study, 2 and 5 mm, ICE, TE and DDM).
Comparisons between different methods MDU and IR values were performed using a
two-tailed paired T-tests for a significance level below 0.05 for IR since it was calculated
for each study and averaged, and below 0.01 for MDU because it was averaged across all
3000 landmarks.
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4.2.5

Dose uncertainty distribution

The uncertainty of a deformed dose distribution was produced by calculating the RDU at
each voxel using a given initial dose distribution and DVF derived from MIM Maestro.
Unlike calculating the RDU at specific landmarks, calculating it at every voxel within a
volume requires an estimation of registration uncertainty for each voxel performed with
DDM. The RDU at each voxel is defined by two values: the upper and lower bounds of
the deformed dose. The deformed dose distribution is where every voxel in the endinspiration study is mapped to a dose value from the dose distribution calculated on the
end-expiration study. Calculating the RDU at every voxel in the end-inspiration study
creates two dose distributions for the upper and lower bounds of the deformed dose
distribution representing all possible levels of dosimetric impact. Visualization of the
dose uncertainty distribution was done by displaying the two dose distributions for the
upper and lower bounds of the deformed dose. Cumulative DVHs for the PTV were
computed for the planned dose and deformed dose containing the upper and lower
bounds.

4.3

Results

4.3.1

DIR error prediction

Linear regression was performed for each DIR prediction method (ICE, TE and DDM) vs
the actual DIR error. Linear regression factors for the DDM method were k = 2.05 (2.022.08) and C = 1.10 (1.01-1.18) mm with a Pearson correlation of R2 = 0.71 (p < 0.001),
for the ICE method k = 0.79 (0.76-0.82), C = 1.86 (1.73 – 1.99) mm and R2 = 0.34 (p <
0.001), and for the TE method k = 0.81 (0.77-0.84), C = 1.76 (1.64-1.89) mm and R2 =
0.37 (p < 0.001).

4.3.2

The range of dose uncertainty

The RDU was calculated for 300 landmarks from the end-inspiration phase on each of the
ten 4DCT images. The results for 31 landmarks receiving the largest radiation dose (from
a single study) are shown in Figure 4-3 using a constant error of 2 mm and 5 mm, the
DDM, and the actual DIR error. For a constant error of 2 mm (Figure 4-3a), the RDU
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values encompass the actual dose value 71% of the time (i.e. the inclusion rate for this
subset of 31 landmarks) because the ranges are not large enough. A 5 mm constant error
(Figure 4-3b) had ranges that were too large because it more frequently overestimated the
dosimetric error than using the constant error of 2mm. For the DDM (Figure 4-3c) the
RDU is more accurate than using 2 and 5 mm errors but not as accurate as using the
actual DIR error (Figure 4-3d).

Figure 4-3: The range of dose uncertainty (RDU) for 31 landmarks with the highest doses from a
representative study calculated using four different measures of DIR error a) 2mm constant b) 5 mm
constant c) DDM d) Actual error. Actual dose (red X) and RDU is shown as a black error bar.
Landmarks are ordered in increasing predicted dose difference from the actual dose. Dose values are
displayed relative to the DIR deformed dose value for each landmark.

4.3.3

Dose uncertainty evaluation

The RDU was evaluated for 3000 landmarks in 10 studies and the average results for
seven prediction methods are shown in Figures 4-4 and 4-5 for the MDU and IR,
respectively. Using the actual DIR error produced the highest average IR of 97%, while
its average MDU value of 2.5 Gy was similar to that of the DDM, ICE and TE methods
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which were 2.49, 2.56, 2.56 Gy, respectively, and the difference was not statistically
significant (p > 0.01). The IR of DDM, ICE and TE were all significantly lower than
using the actual DIR error (p < 0.05) but similar to each other (p > 0.05) with values 86,
88, 86%, respectively. The 2 mm constant error produced the smallest IR of 75% because
it underestimates the DIR error. The 5 mm constant error has the highest average MDU of
3.5 Gy because it overestimates the DIR error the most. MDU’s from DDM, ICE, TE and
mean error was significantly lower than using a constant 5 mm (p < 0.01). IR using
constant 2 mm was significantly lower (p < 0.05) than those obtained by DDM, ICE and
TE methods. IR for the mean error per study was significantly lower (p < 0.05) than those
resulting from DDM and ICE methods.

Figure 4-4: Magnitude of dose uncertainty (MDU) averaged across all 3000 landmarks within 10
4DCT image studies, using the actual DIR error, 2 and 5 mm constant error, distance discordance
metric (DDM), inverse consistency error (ICE), transitivity error (TE), and the mean actual DIR
error per image. Error bars represent the standard deviation across 3000 landmarks.
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Figure 4-5: Inclusion rate (IR) averaged across all 10 4DCT image studies, using the actual DIR
error, 2 and 5 mm constant error, distance discordance metric (DDM), inverse consistency error
(ICE), transitivity error (TE), and the mean actual DIR error per image. Error bars represent
standard deviation across 10 studies.

4.3.4

Dose uncertainty distribution

The dose uncertainty distributions are illustrated in Figure 4-6 for a representative study
using the DDM as the measure of DIR error. Both the upper and lower bounds of the
RDU have worse coverage than the planned dose distribution. The cumulative DVH
curves of the PTV for the deformed dose with the RDU and the planned dose are shown
in Figure 4-7 showing the degradation in target coverage.

75

Figure 4-6: Distributions, of the (a) planned, (b) deformed dose, (c) lower bound, (d) upper bound of
the range of dose uncertainty calculated using DDM. Contour labels: (light blue) PTV and (dark
blue) is gross target volume. Dose prescription was 60 Gy to 95% of the PTV.

Figure 4-7: Cumulative DVH curves for the planned and deformed dose with the upper and lower
bounds illustrating the range of dose uncertainty(RDU) calculated using the DDM. Dose prescription
was 60 Gy to 95% of the PTV.
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4.4

Discussion

DIR accuracy can have a large potential impact on evaluations of radiotherapy treatments
because the dose cumulates across multiple fractions introducing significant anatomical
changes. Unlike other applications of DIR, radiotherapy dose accumulation is performed
at the individual voxel level and errors in DIR can lead to untreated cancer or overirradiated sensitive tissue. Earlier studies of DIR in radiotherapy investigated contour
propagation and dose accumulation. For contour propagation the global accuracy of the
DIR was evaluated, focusing on the ability to define contour edges typically measured
with a DICE coefficient. Kumarosiri et al. evaluated multiple DIR algorithms for
propagating contours for Head and Neck cancer using the DICE coefficient [17]. While
contour propagation is a very useful tool for IGRT, it fails to evaluate a DIR throughout
the interior (and exterior) of the contoured region. Studies presenting dose accumulation
applications are useful in demonstrating the potential of DIR in radiotherapy but fail at
providing the ground truth and range of uncertainty. Abe et al. showed the difference in
DVH parameters using DIR compared to simple DVH parameter addition [18] to
demonstrate benefits of using deformed dose accumulation.
Several studies have compared the results of dose accumulation from different DIR
algorithms [19, 20] revealing that the results are dependent on the specific DIR algorithm.
Typically the investigation of DIR performance and uncertainty is undermined by the lack
of ground truth. In many publications (including an earlier work by Risholm et al. [21])
colour maps and graphs are used to demonstrate the potential DIR uncertainty but do not
consider the actual DIR error. Li et al. used landmarks for the direct correlation between
a registration evaluation method and the actual DIR error but did not consider the dose
implications [22]. Following their approach, we used landmarks to obtain the true DIR
error and impact on dosimetric analysis, across multiple sets of image studies. Though
this does limit the analysis to specific regions of the image, it could also be used with
automatic landmarking software (23, 24) to provide real-time evaluation of DIR
uncertainty. We previously showed the efficacy of using the scale-invariant feature
transform for landmark generation in DIR evaluation and demonstrated that such
landmarks can be a good surrogate for manually selected landmarks [25].
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Error bounds are typically used to demonstrate the level of uncertainty for any measured
or computed value with known limitations or from a sample with a defined statistical
distribution. In this study, we investigated error bars representing the RDU at individual
landmarks using different DIR error prediction methods. The RDU error bars are a
function of both the DIR uncertainty and the local gradient of the dose distribution. For
example, a landmark with large DIR error in a homogenous region of the dose
distribution will have a very low MDU. In Figure 4-2b, the RDU varies greatly even
when using a constant DIR error of 5 mm, because the dose gradient varies greatly
throughout the image volume. The large range in RDU values is the result of using the
maximum and minimum values from each sampling sphere. The extreme values were
selected instead of other descriptors (i.e. 5th and 95th percentile) because it yielded the
highest IR. The MDU and IR metrics were introduced to represent the two most
important properties of an error bar: its size and if a “true” value lies within its bounds.
The ideal RDU would be as small as possible minimizing MDU, while always containing
the true value with an IR = 100%. The RDU calculated from the actual DIR error was
considered the gold standard representing the true dose uncertainty, with the highest IR
while maintaining a minimum MDU. The IR while using the actual DIR error was below
100% because of the limitations in the interpolation of dose values near the boundary of
the sampling sphere. We evaluated different DIR prediction methods on their capability
to represent the RDU.
Testing the impact of DIR error for a number of test voxels is limited to regions where the
landmarks are located and those locations may not be in clinically relevant regions.
Determining the impact of DIR error in all parts of the image would require a method to
quantify or predict DIR error for every point of the image volume. Several studies created
different tools to predict the magnitude of DIR error given specific properties of the
image volume and its deformation [13-15]. In our study, we selected the DDM for DIR
error prediction because it could be tested with 4DCT image studies, considering each of
the 10 phases as separate studies. The other voxel-wise predictors of DIR error (ICE and
TE) performed similarly to DDM with differences in IR of less than 1% and differences
in MDU within 0.1 Gy. The small differences in RDU performance were remarkable
given that DDM had the best correlation with actual DIR error having a Pearson
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correlation coefficient of 0.71 compared to 0.34 for ICE and 0.37 for TE. This remarkable
result is caused by the MDU’s and IR’s insensitivity to small differences in registration
errors produced by different measures because they present the average values across
3000 landmarks with different local dose distributions, whereas the correlation compares
individual landmark errors. The RDU created using the DDM was comparable to the
RDU created using the actual DIR error defined by landmarks. The results using DDM
were also significantly better than the RDU derived from constant error values of 2 and 5
mm having a significantly higher IR and lower MDU respectively. Even the mean DIR
error for each study performed worse than the DDM demonstrating that the
heterogeneous distribution of DIR error throughout a lung volume makes global measures
of DIR error inadequate and should be avoided for this application.
Presently commercial DIR software is being used to calculate the cumulative dose
distributions without considering the impact of registration uncertainty on the risks
associated with poorer tumour control, increased toxicities, and long-term cancer.
Currently in radiation therapy many uncertainties in the treatment planning, delivery and
alignment are accounted for when developing a patient’s treatment plan, but DIR
uncertainty is normally neither included nor propagated across dose fractions. Ideally, the
dose uncertainty should be defined as the dose between the DIR predicted and reality, but
without landmarks located throughout the image space, this is not feasible. Utilizing
different measures of DIR error such as DDM allowed the calculation of a range of
potential dose error throughout the whole volume. By taking the maximum and minimum
dose values within the sphere, the method quantifies the most conservative situation when
the registration error is always in the direction of the largest dose difference. Such
information is valuable for the radiation oncologist by indicating possible areas of
concern. In radiation therapy practice the knowledge of the RDU provides information on
the span of possible dose values, indicates the reliability of the applied DIR algorithm and
can prompt further investigation, including contouring or further imaging. The RDU
evaluation proposed in this work can be included to account for DIR uncertainty limits
when applied to dose accumulations, and allow DIR based dose accumulation to become
standard in radiotherapy clinics. Our future work plans to apply the RDU approach to
other cancer sites using clinical treatment plans to demonstrate how it can impact real
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treatment decisions. The goal is to introduce the RDU evaluation so that it becomes
commonplace whenever DIR is used to assess the impact on a cumulative radiation dose
distribution.

4.5

Conclusion

DIR error is inevitable for any application of repeated image guidance that requires
highly accurate DVF solutions. In our study, we determined the impact of DIR error on
the dosimetric analysis and found that surrogates of DIR uncertainty can provide error
bars for the cumulative dose distribution. Using the landmarks actual displacement error
as the gold standard we evaluated the dose-predictive power of various measures of DIR
error. The RDU evaluation was developed to represent the range in the deformed dose
distribution. Calculation of the RDU required a measure of DIR error and it was shown
that voxel-wise predictions of DIR error (such as DDM) performed best, second only to
using the actual DIR error. It was also confirmed that fixed global measures of DIR errors
are not adequate for determining the RDU when compared to voxel-wise methods. The
RDU calculated using the DDM provided the upper and lower dose limits throughout an
entire deformed dose distribution, not being limited to specific landmarks. Ultimately the
RDU can provide a useful representation of the dosimetric impact of registration
uncertainty for any commercial DIR algorithm, providing clinicians with a more realistic
analysis of how accurately a radiation treatment is converging to the prescribed treatment.
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Chapter 5

5

Online daily assessment of dose change in head and neck
radiotherapy without dose-recalculation

This chapter has been accepted for publication in the Journal of Applied Clinical Medical
Physics By Jason Vickress, Jerry Battista, Rob Barnett and Slav Yartsev. The article will
be open access.

5.1

Introduction

Radiation therapy is a standard treatment option for a variety of cancers where the precise
geometric targeting of tumours can be exploited for achieving better tumour control while
limiting healthy tissue damage. The specific targeting and attenuation of radiation are
unique to the patient’s anatomy at the time of the planning-CT simulation (PCT), but
these conditions are difficult to maintain throughout an entire course of treatment due to
changes in anatomy [1-4]. To account for changes in patient anatomy, plan modification
may be required during the treatment course to ensure accurate targeting. Plan adaptation
has been shown to improve treatment outcomes by promoting better tumour control and
limiting toxicities [5, 6], but this procedure entails additional costs of re-imaging, replanning, and additional quality assurance. Though the potential benefits of plan
adaptation are obvious, no guidelines on decision-making and optimal time for replanning are available.
Plan adaptation has been reported for various treatment sites including lung [7], prostate
[8-10], and head and neck cancers [11, 12]. Across all treatment sites, adaptation is
necessary due to tumour shrinkage, weight loss or other significant anatomical changes
that impact the dose distribution (e.g. lung collapse or re-inflation). Specifically for head
and neck cancers, large volume changes are common and often detected by external
examination or through poor fitting of immobilization devices, but minor changes can go
unnoticed. However, relatively minor anatomy changes may still have a significant effect
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on the dose distribution and are more difficult to discern by visual inspection of anatomy
alone.
More precise and conformal radiation treatments available with modern techniques may
need more plan adaptations to provide consistent target dose coverage and healthy tissue
sparing with a changing anatomy. For making a decision on the necessity of plan
adaptation in clinical practice, efficient daily evaluation of the delivered dose distribution
on the modified anatomy is required. Different methods have been presented on detecting
volume changes [13] and landmark movements [14] but most rely solely on visual
inspection by clinicians. These visual inspections may not be consistent as shown by
inter-observer studies [15]. Several groups have presented adaptation strategies and
schedules throughout treatment [16, 17]. A recent study using the same dataset as in this
study has produced a method of detecting anatomical differences to flag consideration of
plan re-evaluation without considering the dose distribution [18].
Currently, cone beam CT (CBCT) imaging is routinely used for patient alignment and
anatomy monitoring but can also be used for dosimetric assessment of actual radiation
delivery. Dose calculations on CBCTs are possible with the results varying between
reported studies [19-21] because of inferior image quality and tissue densitometry.
Performing reliable analysis of the dose to the target and organs at risk would require
contouring of relevant structures on the daily CBCT image. An attractive alternative is to
employ deformable image registration (DIR) to transfer contour information from the
planning CT study for analysis. DIR has been shown to produce a variety of results
depending on the algorithm used, original contouring accuracy and imaging modalities
(i.e. CT simulation, MRI or CBCT). Unfortunately, registration between different
imaging modalities has been shown to have worse accuracy [22] especially for CBCT
images due to limited image quality and artifacts.
There are two primary effects of anatomical deformations on a radiation treatment: 1)
movement of voxels and regions on interest (ROI) relative to the planned dose
distribution and 2) change of the dose distribution itself due to re-arrangement of voxels
or density changes therein. The current gold standard (GS) for determining whether to
adapt a treatment plan involves a new CT simulation (ReCT), dose calculation and DIR to
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map contours from the PCT. This procedure is time-consuming and expensive but
accounts for both effects of anatomical deformation and is applied when gross anatomical
changes are suspected.
The best alternative without a new CT simulation involves using DIR to warp the
planning CT to match the daily anatomy from the CBCT and perform dose calculation as
proposed by Veiga et al [23] and accounts for both effects of anatomical deformations.
However, the dose recalculation practically can be difficult and time-consuming. It is
usually performed off-line which limits its routine daily use at the treatment unit. What if
you could determine the necessity of plan adaptation without a new CT scan and dose
calculation? Without the re-computation of the dose, only the movement of voxels and
ROI’s relative to the planned dose distribution are considered, but not the change to the
dose distribution. The dose distribution is assumed to be robust and only mildly affected
by the re-arrangement of the voxels. In this study, we explore the results of using the
CBCT without a dose calculation and a CBCT with a dose calculation and compare both
to the current gold standard. The goal is to see if assessing the movement of ROI relative
to the planned dose distribution provides enough dose information to properly trigger the
plan adaptation process, when compared to current clinical practice of visual inspection.

5.2

Methods

5.2.1

Patient studies
For this study, 18 patients who received multi-fractionated radiotherapy for head-

and-neck cancer and had plan adaptation during treatment course were selected. Each
patient had a CT scan taken before treatment (range 4-30 days) and used for planning (i.e.
PCT), daily pre-treatment CBCT studies and another CT re-taken during treatment
(ReCT) when anatomy changes were deemed significant (day “X”). Significant changes
included sensitive structures moving into high dose regions, tumour moving out of this
region or excessive weight loss by the patient. Both PCT and ReCT studies were obtained
on a 120 keV Phillips Big Bore CT scanner (Philips Healthcare, Fitchburg, WI, USA)
with a 512 x 512 image size, 0.9-1.2 mm resolution, and 3 mm slice thickness. CBCT
scans were performed every 1 to 5 fractions with the onboard imaging available on
Varian iX and True Beam treatment units (Varian Medical Systems, Palo Alto, CA, USA)
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using 100 keV with a 512 x 512 or 384 x 384 image size, 0.5 – 0.65 mm resolution and
2.5 – 2 mm slice thickness. Treatment plans had prescribed doses ranging 50-70 Gy to the
planning target volume (PTV) in 30 to 35 fractions using volumetric arc therapy (VMAT)
with two 360◦ arcs and included 1 or 2 target volumes. Specifically, 15 patients had only
one target, 3 had two targets and all patients had a larger nodal volume overlapping all
targets prescribed to a lower dose. Treatment planning and dose calculations were
performed on a Pinnacle treatment planning system (version 9.10, Philips Healthcare,
Fitchburg, WI, USA) using Pinnacle’s collapsed cone convolution superposition
algorithm [24] using a dose grid of 3×3×3 mm. All image registrations (both rigid and
deformable) were performed with software from MIM Maestro (version 6.5 MIM
Software Inc., Cleveland, OH, USA) using the default DIR algorithm applying an
intensity based free form algorithm, with a sum of squared differences similarity metric
[25]. The mean registration error using MIM Maestro between two kVCT’s was shown to
be 1.7 mm by Kirby et al. [22] using a deformable Head and Neck phantom.

5.2.2

Dose distribution estimation

To determine the necessity of plan adaptation, an estimation of the dose distribution “of
the day” was required and three estimation methods are presented and compared to the
current gold standard which requires a re-planning CT. The first method (CBCTP) used
DIR to map the contours from the PCT to the daily CBCT with the planned dose
distribution rigidly registered to the daily CBCT as shown in figure 1.

Figure 5-1: Illustration of the CBCTP method for the evaluation of the need for plan adaptation using
the DIR of planning CT to daily CBCT study and the planned dose distribution. DIR – deformable
image registration, RR – rigid registration.
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The second method (CBCTR) used the DIR to map the contours from the PCT to the daily
CBCT with the recalculated dose (from the ReCT) rigidly registered to the daily CBCT.
The third method (ReCTP) used the DIR to map the contours from planning CT to the
ReCT with the planned dose distribution rigidly registered to the ReCT. The gold
standard method (ReCTR) applied DIR to map contours from the PCT to ReCT with the
recalculated dose on the ReCT. Both dose distributions (planned and recalculated) were
obtained using the original treatment plan parameters and beam; the plan was not reoptimized. The rigid registration process used 6 degrees of freedom and simulated the
alignment of the CBCT study to PCT (or ReCT) performed by the radiation therapists in
the clinic before each fraction. In total, four separate methods estimated the daily dose
distribution using the CBCT or ReCT as the secondary CT study, with the planned or
recomputed dose. For clarity, each method was referred to by the secondary image used
(CBCT or ReCT) and if the planned or ReCT dose was used, denoted by subscript P or R,
respectively. All dose estimation methods are illustrated in figure 2, showing all four
investigated combinations.

Figure 5-2: Schema describing the daily dose estimation using DIR from the planning CT to either
the daily CBCT or re CT study (ReCT). Two different dose distributions computed on the PCT or
ReCT are transferred to the moving image using a 6 degree of freedom rigid registration. The gold
standard method is highlighted in yellow using the ReCT and recomputed dose. Day X is when ReCT
was ordered due to observed significant anatomical changes.
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5.2.3

Voxel-to-voxel dose comparison

The clinically relevant comparison of the dose results obtained by different estimations
requires evaluation on a voxel-to-voxel basis. Every voxel in the PCT study can have a
different dose value in fraction X (when ReCT was ordered), depending on the secondary
CT study for image registration and the dose distribution. Comparison with any other
method is done by calculating the relative dose difference to the GS (RD j) for a specific
structure j across each individual voxel i:
=

∑

∑

(

)
(

( )
)

× 100%

(1)

between a test method (T) and GS averaged over all Nj voxels within all 18 patients p.
Voxel-to-voxel analysis was performed for the right and left parotids because they were
present in all image studies, incurred significant deformation and are frequently
positioned close to the target volume. The analysis was also performed for the spinal cord
because it is a clinically important structure.

5.2.4

Test for the necessity of adaptation

In practice, the estimations of dose distribution changes would be used to determine if a
current plan delivery is not within clinical dose tolerances and needs adaptation. For our
dose distribution estimation methods, adaptations were considered necessary if the
following dose tolerances were exceeded: mean dose to parotid equal or above to 26 Gy,
max dose to spinal cord equal or above 50 Gy or dose to 95% of the PTV below the
prescription dose. Using two of the methods, CBCTP and CBCTR, dose values were
calculated and compared to clinical tolerances to see which method would accurately
trigger plan adaptation, when compared to the gold standard (ReCTR). Any parotid with a
planned mean dose equal or above 26 Gy was excluded from this test since the organ was
already planned to receive greater than the tolerated dose. The spinal cord is an important
organ for head and neck radiotherapy planning, but was not considered for the necessity
of adaptation test since the threshold for a max dose of 50 Gy was only crossed by one
patient.
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For the PTV the dose was determined at each voxel using CBCTP and CBCTR methods.
The threshold criterion for adaptation was for 95% of the volume (D95) to be below the
prescribed dose. The D95 parameters were selected because following recommendations
for evaluating the target coverage [26]. Only the primary PTV was analyzed for each
patient.
Evaluation of the clinical decision to adapt or not relied on the compliance with both
parameters: the parotid mean dose and D95 to the PTV. To simulate a conservative
treatment situation the mean parotid dose and max spinal cord dose was rounded to the
nearest integer, for example, 25.6 Gy is rounded to 26 Gy. The results were reported as
the number of unnecessary adaptations (adapting, when within tolerance) and missed
adaptations (not adapting, when tolerances were exceeded).

5.3

Results

5.3.1

Voxel-wise dose comparison

The relative dose difference RDj given by equation (1) for each method are shown in
table 1 for the ipsilateral and contralateral parotids and spinal cord. The error caused by
only the changed dose distribution is presented by the ReCTP row and the CBCTR row
represents the error caused only by the DIR between different imaging modalities. CBCTP
row represents the error when both effects were present.
Table 5-1: Relative voxel-wise dose difference from gold standard (ReCTR) (RDj) for ipsilateral and
contralateral parotids and spinal cord, averaged over 18 patients. Standard deviation is displayed in
brackets.

Secondary image and
dose distribution

Ipsilateral Parotid

Contralateral
Parotid

Spinal cord

ReCTP
CBCTP
CBCTR

8 % (5.7 %)
12.7 % (9.5 %)
7.5 % (4 %)

7.9 % (5 %)
13.5 % (7.8 %)
7.7 % (4.5 %)

3.8 % (1.6 %)
5.7 % (2.4 %)
4 % (2 %)
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5.3.2

Test for the necessity of adaptation

The parotid mean dose estimates using CBCT P and CBCTR are compared relative to the
26 Gy threshold to the gold standard (ReCTR) in figures 3a and 3b, respectively. The
number of parotids that were incorrectly labelled as either greater than or less than 26 Gy,
out of 15 tested parotids was five for CBCTP and one for CBCTR. The D95 estimates
relative to the dose prescription for CBCTP and CBCTR are compared to the gold standard
in figures 4a and 4b, respectively. The number of patients where the CBCT-based
prediction was different from the gold standard on their PTV D95 parameter (out of 18
patients) was one for both CBCTP and CBCTR.

Figure 5-3: Predicted mean dose using a) CBCTP and b) CBCTR methods compared to ReCTR (gold
standard) for 15 parotid glands. Clinical threshold of 26 Gy is shown by solid lines. ReCTR is the DIR
to ReCT using the recalculated dose. CBCTP is the DIR to daily CBCT using the planned dose.
CBCTR is the DIR to daily CBCT using the recalculated dose.
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Figure 5-4: The difference between predicted D95 and the prescribed dose for the PTV for using a)
CBCTP and b) CBCTR methods compared to ReCTR (gold standard). Values are presented as the
difference from the prescribed dose. ReCTR is the DIR to ReCT using the recalculated dose. CBCTP
is the DIR to daily CBCT using the planned dose. CBCTR is the DIR to daily CBCT using the
recalculated dose.

To simulate a clinical decision-making situation, the results for both parotids and PTVs
were combined to determine whether to adapt or not based on the dose predictions from
CBCTP or CBCTR methods. Clinically, the plans for all 18 patients were adapted using a
conservative approach based on anatomical changes alone but according to our dose
analysis, only 7 were outside of tolerance leaving 11 potentially unnecessary adaptations.
Using the CBCTP method there would have been only 4 unnecessary adaptations without
missing any required adaptations. For CBCTR (with the recomputed dose) there would
have been 2 unnecessary adaptations while also not missing any required adaptations.

5.4

Discussion
In a standard workflow, the only dose distribution always available is the one

calculated using the initial CT simulation for planning purposes. Theoretically, the dose
gradients from the planned dose distribution indicate what dose differences may occur
due to specific anatomical changes. Dose gradients are mainly defined by the original
beam geometry relative to the planned iso-centre, which is not affected by deformation.
Without extensive deformation, these gradients can be maintained and could predict dose
change, when combined with a deformation field. However, with large volume or density
reductions within the beams path significant changes to the dose distribution can result,
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which could lead to missed adaptations, if no dose calculation is performed. But very
large volume/density changes are clearly visible by visual inspection on imaging and
would be flagged and trigger adaptation by a therapist.
The average relative dose differences RDj for each organ presented in table 1 show that
for both parotids and spinal cord the RDj from the CBCTR method (which is a result of
DIR error alone) is similar to the results from the ReCTP method, which is the error from
using the plan instead of the recomputed dose. The CBCTP RDj includes both sources of
error but is less than the sum of errors in ReCTP and CBCTR methods.
It has been shown that DIR error is specific to the algorithm used [27, 28] and image
quality [22]. In this study, only one commercial algorithm was used to evaluate the utility
of applying DIR to CBCT studies using an unmodified commercial product. More
accurate dose estimations could be performed if registration error was known and
accounted for as demonstrated in our previous work [29]. Typical plan adaptation
strategies revolve around re-planning on the CBCT study using DIR to propagate
contours and evaluate dose [30-32]. Two publications by Veiga et al. have evaluated the
process of using DIR to CBCT studies for determining daily dose [23] and accumulated
dose with different DIR algorithms [28], but in both cases dose computations are needed
for each fraction. In this study, DIR of the daily CBCT study is proposed to evaluate
anatomical changes without a re-scan of the patient or dose calculation using a
commercial DIR algorithm.
Practically speaking, DIR procedures can help physicians to decide when to adapt their
radiation treatment plans. From the results presented in figures 3 and 4, the clinical
decision to re-plan all 18 of these cases was not necessary, with 11 of the original patient
plans still within clinical tolerances. Clinical decisions of plan adaptation were made
before the re-scan using personal experience, which explains the discrepancy in
adaptation rates between our GS and what was decided clinically. Our results have shown
that both methods using daily CBCT studies (CBCTR and CBCTP) yielded very
conservative results and missed no required adaptations. If the simplest prediction method
(CBCTP) was used, only four patients would have been unnecessarily re-scanned and
adapted. This demonstrates that using the DIR to the CBCT of the day without a dose
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calculation in CBCTP method can determine when to adapt a treatment plan better than
what was done clinically avoiding a number of unnecessary CT simulations and replanning efforts. Performing an additional dose calculation in CBCTR caught two
additional unnecessary plan adaptations at the cost of additional computation time, while
without a dose computation the procedure can be completed within one minute allowing
for an efficient “adapt or not” decision online.

5.5

Conclusion

Improvements in IGRT and conformal radiation delivery have made adaptive radiation
therapy a reality, but steps need to be taken to ensure its efficiency. Practical
implementation requires an efficient method of daily evaluation and decision-making to
determine when plan adaptation is truly necessary. The method of dose evaluation using
on-board CBCT imaging alone is limited by the necessity for dose calculation, contouring
and image registration. We have shown that the daily CBCT image mapped back to the
planning CT without a dose calculation can provide sufficient information for the
important decision of when to re-plan. The goal is to prevent the use of unnecessary
additional CT simulations and dose computations with a quick online evaluation. Further
research needs to be performed with more patients and other treatment sites including
abdomen and thorax and for treatment techniques that will produce a different landscape
of dose gradients.
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Chapter 6

6

Conclusion and future work

6.1

Summary of findings

This thesis has demonstrated (1) the significance of using patient data to guide physician
decision making in radiation therapy, (2) the importance of including registration
uncertainty, when applying DIR for dose accumulation, and (3) the need for outcomedriven decision making schematically presented in Figure 1-7. In this chapter, the major
findings of the four studies comprising this thesis and future work are summarized.

6.1.1

Data-driven decision making in radiation therapy

In the past, treatment decisions in radiation therapy, including dose prescriptions, have
been made based on the physician’s experience including findings from clinical trials.
With rapidly evolving technology and development of new treatment techniques, clinical
trials cannot keep pace and are only attempted when large payoffs are expected.
Unfortunately, current clinical trials cannot effectively optimize treatment prescription
and delivery parameters for specific disease pathologies and patient characteristics. To fill
this void and provide truly personalized medicine, real-time data-driven decision making
is required, utilizing the large quantities of data available in this era of “Big data” [1].
Data-driven decision making requires large amounts of patient data to construct models
predicting patient outcomes, including survival, disease control, and toxicity based on
patient characteristics and available treatment options. Chapter 2 tackled this problem for
patients suffering from hepatocellular carcinoma and metastatic liver cancer to predict
overall survival and determine the candidacy for curative vs palliative treatment. The
results of chapter 2 were two nomograms predicting overall survival for both patient
groups, including the patient’s disease burden and liver function. Nomograms act as
predictive models to guide a physician’s decision on how to best treat based on the
patient’s pre-treatment information providing the link between patient data and treatment
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decisions as shown in Figure 1-7. Chapter 2 demonstrated that using routinely collected
patient data can help guide physicians with treatment decisions, and highlight new areas
of research, that will improve patient care. For example, the prescribed radiation dose was
not found to be a significant variable predicting overall survival with a p-value of 0.1 for
the HCC model. Prescribed radiation dose only describes what was planned, not
necessarily how the radiation was actually delivered. It can be speculated that using the
actual delivered dose (acquired through DIR based accumulated dose) should improve the
models of survival, which led to the work with DIR in chapters 3 and 4. With improved
predictive models patients can receive treatments personalized for their unique biology.
Aside from using patient data for pre-treatment decision making, it can also improve midtreatment decision making as to when to adapt a treatment plan. Currently, all midtreatment decisions are made based on the visual inspection of alignment devices (i.e.
masks) or daily imaging (i.e. CBCT or 2D kilovoltage) by physicians. The method
presented in Chapter 5 is not replacing clinical decisions but providing physicians with
the dosimetric changes automatically and reliably in less than one minute before every
treatment fraction. Additionally, the results of the study in chapter 5 demonstrated that the
decision for plan adaptation could be made without the need for manual contours or a
dose calculation. Typically, accurate dose analysis would benefit from a new dose
calculation on the modified anatomy, but the results from chapter 5 demonstrate that in
order to predict significant changes to a dose distribution, it is not always required. The
conclusion from chapter 5 demonstrated that applying data-driven decision making can
provide physicians with the daily dosimetric changes and make adaptive radiation therapy
more reliable and cost-effective by initiating a re-planning procedure only when
necessary.

6.1.2

Including registration uncertainty of DIR for dose accumulation

Deformable image registration is becoming a common tool in radiation therapy allowing
for the propagation of contours between different image sets and the accumulation of
dose between sets of images. Unfortunately, DIR inherently contains variable levels of
accuracy creating significant uncertainty in any results it produces. Originally only rigid
registration (including translations and rotations) was used in radiation therapy for
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alignment of treatment images and target delineation, and any error could be visualized
and quantified as a single value. DIR is defined by thousands of 3D deformation vectors,
each having its own associated error vector. When DIR is used in conjunction with
another 3D quantity such as absorbed dose the effect of registration error is magnified.
For DIR to be effectively used in radiation therapy, the routine evaluation of DIR error
and its impact on cumulative dose is required.
In chapter 3, a new novel method for the evaluation of DIR was presented using an autolandmarking method based on the scale invariant feature transform (SIFT). Landmarking
methods find corresponding points in a pair of images and tests how well the DIR can
match the same landmark points. Previously landmark pairs could only be located
manually requiring significant human resources, reserving their use to algorithm
benchmarking [2, 3] and research [4]. The method presented in chapter 3 created
landmarks comparable to high-quality gold standard landmarks and reproduced local
deformation values with an ICC value of 0.96. The primary limitation of automatic
landmarks is the number and distribution which are heavily influenced by the type and
quality of images used. For frequent routine evaluation, only a small number of
landmarks representative of the anatomy and the dose distribution are required, compared
to the large number of landmarks required for DIR algorithm benchmarking. With the
method from chapter 3, the routine evaluation of DIR is possible enabling the accurate
daily use of DIR in the clinic. Accurate DIR with IGRT is the best method to determine
the cumulative dose distribution providing the link between what was planned and
delivered as shown in Figure 1-7.
One of the primary uses of DIR in radiation therapy is the accumulation of dose
throughout a multi-fraction treatment using the CBCT studies provided by IGRT. Dose
accumulation uses the DVF to map the dose from individual fractions back to the original
treatment plan to determine the actual delivered dose. The accuracy of a dose
accumulation is determined by the accuracy of each vector within the deformation field
multiplied by the local dose gradient. Previously, the only option was to apply the best
available DIR algorithm, with no account of the registration error. The dose accumulation
error cannot be easily included because of the distribution of registration errors
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throughout an image volume. If the registration error is high in regions with a large dose
gradient, there will be a large dose accumulation error and a homogeneous dose region
with a low dose gradient will have a low dose accumulation error. Chapter 4 presented a
method of incorporating the distribution of registration error into the dose accumulation
process to provide the range of accumulated doses. The method in chapter 4 was also
shown to work with DIR uncertainty values calculated from statistical, or consistency
metrics. Currently, the best option is to cumulate radiation dose assuming the registration
is 100% accurate, but with the method presented in chapter 4, a realistic range of
cumulative dose values can be obtained. With a realistic range of delivered dose values,
an accurate account of radiation treatment can be obtained and fed into an outcomedriven decision-making process as shown in Figure 1-7. With the real delivered dose
stronger predictive models can be produced to guide physicians in their treatment
decision for each new patient.

6.2

Future work

6.2.1

Automatic DIR evaluation of different disease sites.

In chapter 3 an auto-landmarking algorithm was applied and evaluated for lung CT
studies, demonstrating its ability to quickly evaluate DIR. To increase the viability of
auto-landmarking methods, tests with other treatment sites and imaging modalities should
be performed. Important disease sites exhibiting large amounts of deformation during
radiation therapy include head and neck, breast, and cancers within the abdomen and
pelvis (i.e. prostate). This land-marking method should also be tested on different
imaging modalities including CBCT and MRI, investigating the method’s performance
between like (i.e. CBCT-CBCT) and different modalities (i.e. MRI-CBCT). Effective
testing of a landmarking method requires manual gold standard landmark sets similar to
the gold standard landmarks used in chapter 3. With gold standard landmarks for each
treatment site and imaging modality, the presented algorithm can be tested and optimized
with the goal of being introduced for routine DIR evaluation. It is also important to test
other land-marking algorithms and compare them to those generated by SIFT. For
example, other land-marking algorithms include an edge based region detector [5] or
Speeded-up robust feature detection (SURF) [6]. There is also potential to improve upon
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the current SIFT implementation to improve landmark yield and quality as shown in
Yang et al. [7]. With the routine evaluation of DIR, it can be used freely to assess daily
anatomy or determine the cumulative dose distribution and be correlated with outcomes.

6.2.2

Clinical application of DIR with uncertainty.

DIR continues to grow in popularity in radiation therapy, being included in almost every
treatment planning system and medical imaging software. From the methodologies and
data in chapters 3 and 4, the accuracies of DIR algorithms vary significantly and they
need to be routinely evaluated, and the inaccuracies incorporated into any resulting
analysis. To achieve this, the auto-landmarking methods presented in this thesis can be
included in any DIR package, and the resulting error on each vector can be used to
interpret the final error in the cumulative dose analysis. The final result of any DIR
should provide error bars on the cumulative dose distribution to better understand what
was actually delivered and how it correlates with patient outcomes.

6.2.3

Modelling treatment outcomes with more realistic delivered dose.

Traditionally, effects of radiation therapy have been modelled based on planned dose
parameters, for example, the dose to 95% of the target volume. Historically, only
important dose parameters from a radiation treatment plan were recorded and linked
radiation effects and treatment. With newer technologies and techniques, detailed data are
available describing the specific spatial distribution of radiation dose, relative to different
tissue types and organs. The spatial distribution of the delivered radiation dose could then
help to further explain the effects of the radiation dose, including radiation-induced
toxicity and tumour control. The next step is to include daily image guidance and DIR to
know the actual delivered dose to patients and provide the most detailed account of a
radiation treatment.
Current forms of DIR are not accurate enough to be used for dose accumulation without
accounting for the registration uncertainty. In this thesis, two methods have been
presented to allow for a more accurate use of DIR through the incorporation of
registration uncertainty. When DIR is applied for dose accumulation it can be evaluated
using the auto-landmarking method presented in chapter 3 and determine the spatial
distribution of registration error. With the known spatial distribution of registration error,
103

the dose accumulation error can be calculated using the method from chapter 4 on each
individual treatment fraction. Information about the dose accumulation error can
determine which patients have an accurate account of their delivered radiation treatment
and can be correlated with outcomes. Although dose uncertainties are vital for developing
tools for a physician’s decision making, clinical significance comes down to absolute
cumulative dose to regions of interest for both TCP and NTCP assessment. Further
studies can produce predictive models between the “real” delivered dose and patient
outcomes to be implemented in outcome-driven decision making as shown in Figure 1-7.
The ultimate goal is to use the record of real radiation dose to further improve predictive
models and work towards personalized medicine using the already available patient data.
The goal of this thesis is to present methods for the incorporation of outcome-driven
decision making in radiation therapy and facilitate personalized treatments for patients
based on their own specific biology. It is hoped that this work will provide the roadmap to
implement outcome-driven decision making in radiation therapy clinics and utilize the
large amount of available clinical data to significantly improve patient care.
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Appendix B: Description of clinical parameters and tools from
chapter 2
B.1 Important clinical measures for liver cancer patients
In the diagnosis and treatment of liver cancer there are a number of important clinical
measures that are used to describe a patients overall liver function. Bilirubin is a protein
found in the blood and is created in the liver with high levels being indicative of liver
disease. Serum albumin is the most abundant protein found in human blood, and low
levels of serum albumin are also indicative of liver disease. Ascites describes a patient
retaining water within their liver and another indicator of liver disease. Child Pugh score
is a common measure of a patients liver function ranging from A to C indicating good to
poor liver function respectively. Child Pugh score is calculated from the combination of
different clinical factors including bilirubin, serum albumin and ascites.

B.2 Interpreting Cox proportional hazard model results.
The Cox proportional hazard model is used to find the association between specific
variables (either continuous or binary) and overall survival. The Cox proportional hazard
model is a linear regression solving for equation 1, where λ(t) is the hazard rate, λo(t) is
the baseline hazard function, X1-Xn are the different variables and β1-βn are the model
parameters determined for each variable.
( )=

( )exp(

+⋯+

)

(1)

Hazard rate describes the risk of death and a higher hazard rate describes lower survival.
The primary results of a Cox proportional hazard model are the β values, hazard ratio
(with 95% confidence interval) and p-values. β values describe the relationship each
variable has on survival for example a positive β value indicates a higher hazard rate and
lower survival. Hazard ratios also describe the effect each variable has on overall
survival, hazard ratio > 1 describes poor survival and hazard ratio < 1 describes better
survival. A p-value measures the significance of the variable on overall survival, with a pvalue < 0.05 indicating a significant result.
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Cox proportional hazard model results are presented for both univariate and multivariate
analysis. Univariate analysis describes the individual effect of each variable on survival.
Multivariate analysis describes the effect each variable has on survival when combined
with other significant variables chosen for the final model.

B.3 Applying a nomogram
Clinical nomograms visualize predictive models created using a cox proportional hazard
model for application in the clinic. A diagram describing the process of a nomogram is
presented in figure B-1, describing how the score is summed and converted to a one year
and six month survival probability.

Figure B-1: Diagram describing the use of a clinical nomogram, using clinical variables to determine
the probability of one year and six month survival.
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Appendix C: Description of the Scale Invariant Feature
Transform (SIFT)
C.1 Scale invariance
The Scale Invariant Feature Transform (SIFT) was engineered to match points between
two images regardless of relative scale (scale invariant). If two images are taken with the
same imaging system, they can be compared and matched based on the voxel intensities
directly .When the imaging systems are different direct voxel comparison is no-longer
valid because of scaling differences. In-order to compare two images together regardless
of scale the difference of Gaussian images is selected as presented in Lowe et al [1].
The difference of Gaussian images is computed by convolving an image with the
Gaussian filter with a defined scaling σ (equation 1) and subtracting it from an image
convolved with a Gaussian filter with different scaling kσ (equation 2).
( , , , )=
(
( , , ,

(
√

)/

)

)= ( , , ,

∗ ( , , )

)− ( , , , )

(1)
(2)

The result is an image describing the gradients within the image, regardless of scale. Also
the Laplacian of the Gaussian can be approximate from the difference of Gaussian
images, using a modified heat equation using σ in place of t (shown in equation 3).
∇

=

≈

( , , ,

)

( , , , )

(3)

The result is an approximate Laplacian of the Gaussian at every point in the image
volume and at different scaling values construct a 4D (x,y,z,σ) matrix used to locate
unique points.

C.2 Finding unique points
Once the 4D matrix (x,y,z,σ) of the Laplacian of the Gaussian is constructed the next step
is to find local maximum and minimum values. This is performed by finding the local
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maximum and minimum voxels when compared to all the nearest neighbors across all 4
dimensions (80 neighboring points).

C.3 Removal of edge points
With all the unique points located the next step is to remove points that are located on an
edge because they can have strong difference of Gaussians while not actually being
unique. This is performed by looking at the magnitude of the primary and secondary
eigen-vectors (direction with the highest rate of change). If the magnitude of the primary
eigen-vector is Hmax times greater than the secondary eigenvector it is located on an edge
and excluded as a unique point. The parameter Hmax is tuned for the specific imaging
system being used.

C.4 Point localization
All landmark locations are limited by the resolution of the image volume being used, but
perhaps the true unique point could lie in between 3D voxels. To interpolate between
voxels and localize the approximate maximum or minimum a 2 nd order Taylor expansion
is used (shown in equation 4) with x = (x,y,z,σ). To locate the maximum and minimum the
derivative of the Taylor series is set to zero and solved for the localized point v (shown in
equation 5).
( )=

+

+ 0.5

(4)

=−

(5)

Once the point is localized in 4D, the new value is measured from the Taylor series and if
it is below rthresh it will be excluded. The rthresh parameter is selected to remove points with
low contrast.

C.5 Point descriptors and matching
With all unique points located in an image study the next step is to create descriptors
describing each point. The first step is to subdivide the surrounding voxels into 4x4x4 sub
volumes each containing 4x4x4 voxels, totaling 16x16x16 voxels centered on the unique
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point being described. For each voxel the gradient magnitude and direction (both
azimuthal and elevation directions) is computed. Now each sub volume includes the
magnitude and direction for 4x4x4 voxels and the gradient magnitude is binned into an 8
by 4 matrix based on their azimuthal (8 directions between 0 and 360) and elevation (4
directions between 0 and 180) directions respectively. To have more distinct feature
matching the gradient magnitudes can be scaled based on their distance from the center of
the sub volume. The final descriptor is a 4x4x4x8x4 matrix describing each unique point.
With each unique point in two image volumes having a descriptor the next step is to
match like points between each image. The fastest matching method is to convert each
descriptor (4x4x4x8x4) into a 2,048 dimensional vector and finding the Euclidian
distance between every possible unique point pair. For example for one unique point you
would calculate the Euclidian distance between the 2,048 dimensional vectors from all
points in the other image and find the point with the smallest “Euclidian distance”. If the
next closest point has a Euclidian distance 1.66 times greater than they are matched
together. The distance to the next most similar point (1.66) is chosen to find the balance
between the number and quality of landmarks, a smaller multiplier would yield more
points with potentially less similarity. The end results are landmarked points between two
3D volumes.

C.6 Optimization
When implementing a SIFT algorithm there is a balance between the number and quality
of matched points. This balance is changed by changing the kσ, Hmax, rthresh and distance
to next most similar point. Each of these parameters affects how many unique points are
considered or the matching criteria and they need to be optimized for the specific type of
images (etc. CT or MRI) or what is being imaged (etc. thorax vs brain).
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